Said M. Sebti - Publications

Affiliations: 
University of South Florida, Tampa, FL, United States 
Area:
Biochemistry, Cell Biology

382 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Walton K, Walker K, Riddle M, Koehn BH, Reff J, Sagatys EM, Linden MA, Pidala J, Kim J, Lee MC, Kiluk JV, Hui JYC, Yun SY, Xing Y, Stefanski H, ... ... Sebti SM, et al. Dual JAK2/Aurora kinase A inhibition prevents human skin graft rejection by allo-inactivation and ILC2-mediated tissue repair. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. PMID 34668635 DOI: 10.1111/ajt.16870  1
2021 Kazi A, Chen L, Xiang S, Vangipurapu R, Yang H, Beato F, Fang B, Williams TM, Husain K, Underwood PW, Fleming JB, Malafa MP, Welsh EA, Koomen JM, Trevino JG, ... Sebti SM, et al. Global Phosphoproteomics reveal CDK suppression as a vulnerability to KRAS addiction in Pancreatic Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33879459 DOI: 10.1158/1078-0432.CCR-20-4781  1
2021 Pidala J, Walton K, Elmariah H, Kim J, Mishra A, Bejanyan N, Nishihori T, Khimani F, Perez L, Faramand RG, Davila ML, Nieder ML, Sagatys EM, Holtan SG, Lawrence NJ, ... ... Sebti SM, et al. Pacritinib combined with sirolimus and low-dose tacrolimus for GVHD prevention after allogeneic hematopoietic cell transplantation: Preclinical and Phase I trial results. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33753457 DOI: 10.1158/1078-0432.CCR-20-4725  1
2020 Boucher JC, Li G, Kotani H, Cabral ML, Morrissey D, Lee SB, Spitler K, Beatty NJ, Cervantes EV, Shrestha B, Yu B, Kazi A, Wang X, Sebti SM, Davila ML. CD28 co-stimulatory domain-targeted mutations enhance chimeric antigen receptor T-cell function. Cancer Immunology Research. PMID 33188139 DOI: 10.1158/2326-6066.CIR-20-0253  1
2020 Walton K, Fernandez MR, Sagatys EM, Reff J, Kim J, Lee MC, Kiluk J, Hui JYC, McKenna D, Hupp M, Forster C, Linden MA, Lawrence NJ, Lawrence HR, Pidala J, ... ... Sebti SM, et al. Metabolic reprogramming augments potency of human pSTAT3-inhibited iTregs to suppress alloreactivity. Jci Insight. PMID 32255769 DOI: 10.1172/Jci.Insight.136437  1
2020 Yang H, Xiang S, Kazi A, Sebti SM. The GTPase KRAS suppresses the P53 tumor suppressor by activating the NRF2-regulated antioxidant defense system in cancer cells. The Journal of Biological Chemistry. PMID 32001619 DOI: 10.1074/Jbc.Ra119.011930  1
2019 Karasic TB, Chiorean EG, Sebti SM, O'Dwyer PJ. A Phase I Study of GGTI-2418 (Geranylgeranyl Transferase I Inhibitor) in Patients with Advanced Solid Tumors. Targeted Oncology. PMID 31372813 DOI: 10.1007/s11523-019-00661-5  0.01
2019 Francois RA, Zhang A, Husain K, Wang C, Hutchinson S, Kongnyuy M, Batra SK, Coppola D, Sebti SM, Malafa MP. Vitamin E δ-tocotrienol sensitizes human pancreatic cancer cells to TRAIL-induced apoptosis through proteasome-mediated down-regulation of c-FLIP. Cancer Cell International. 19: 189. PMID 31367187 DOI: 10.1186/S12935-019-0876-0  1
2019 Sebti SM, Kazi A, Xiang S, Yang H, Chen L, Kennedy P, Ayaz M, Fletcher S, Cummings C, Lawrence HR, Beato F, Kang Y, Kim MP, Delitto A, Underwood PW, et al. Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31227505 DOI: 10.1158/1078-0432.Ccr-18-3399  1
2019 Boucher JC, Li G, Kotani H, Cabral M, Morrissey D, Lee SB, Spitler K, Beatty N, Shrestha B, Yu B, Kazi A, Wang X, Sebti S, Davila ML. Mutation of the CD28 Co-Stimulatory Domain Confers Enhanced CAR T Cell Function Blood. 134: 248-248. DOI: 10.1182/Blood-2019-122954  1
2019 Kazi A, Xiang S, Yang H, Chen L, Kennedy P, Ayaz M, Fletcher S, Cummings C, Lawrence H, Beato F, Yang Y, Kim MP, Delitto A, Underwood P, Fleming JB, ... ... Sebti SM, et al. Abstract 3088: Farnesyl/geranylgeranyl transferase dual inhibitor thwarts mutant KRas-driven patient-derived pancreatic tumors Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3088  1
2019 Kazi A, Xiang S, Yang H, Delitto D, Trevino J, Jiang RH, Ayaz M, Lawrence H, Kennedy P, Sebti SM. Abstract 1310: Abrogation of KRas-addicted tumors by GSK3 suppression-mediated upregulation of β-catenin and c-myc Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1310  1
2018 Kazi A, Xiang S, Yang H, Delitto D, Trevino J, Jiang RHY, Ayaz M, Lawrence HR, Kennedy P, Sebti SM. GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors. Nature Communications. 9: 5154. PMID 30514931 DOI: 10.1038/s41467-018-07644-6  1
2018 Carbone M, Amelio I, Affar EB, Brugarolas J, Cannon-Albright LA, Cantley LC, Cavenee WK, Chen Z, Croce CM, Andrea A, Gandara D, Giorgi C, Jia W, Lan Q, Mak TW, ... ... Sebti SM, et al. Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine. Cell Death and Differentiation. PMID 30323273 DOI: 10.1038/S41418-018-0213-5  1
2018 Bazi F, Mounir B, Hamza M, Sebti S. A Mild and Efficient Method for the Synthesis of Acylals from Aromatic Aldehydes and Their Deprotections Catalyzed by Synthetic Phosphates under Solvent-Free Conditions Green and Sustainable Chemistry. 8: 334-344. DOI: 10.4236/Gsc.2018.84023  0.01
2018 Vangipurapu R, Chen L, Kennedy P, Morrison KC, Hergenrother PJ, Sebti SM. Abstract 1669: Identification of mutant KRas-Raf-1 binding disruptors Cancer Research. 78: 1669-1669. DOI: 10.1158/1538-7445.Am2018-1669  1
2017 Kuchay S, Giorgi C, Simoneschi D, Pagan J, Missiroli S, Saraf A, Florens L, Washburn MP, Collazo-Lorduy A, Castillo-Martin M, Cordon-Cardo C, Sebti SM, Pinton P, Pagano M. PTEN counteracts FBXL2 to promote IP3R3- and Ca(2+)-mediated apoptosis limiting tumour growth. Nature. PMID 28614300 DOI: 10.1038/Nature22965  0.01
2017 Nishimura S, Mishra-Gorur K, Park J, Surovtseva YV, Sebti SM, Levchenko A, Louvi A, Gunel M. Combined HMG-COA reductase and prenylation inhibition in treatment of CCM. Proceedings of the National Academy of Sciences of the United States of America. PMID 28500274 DOI: 10.1073/Pnas.1702942114  0.01
2017 Husain K, Centeno BA, Coppola D, Trevino J, Sebti SM, Malafa MP. d-Tocotrienol, a natural form of vitamin E, inhibits pancreatic cancer stem-like cells and prevents pancreatic cancer metastasis. Oncotarget. PMID 28404939 DOI: 10.18632/Oncotarget.15767  1
2017 Betts BC, Veerapathran A, Pidala J, Yang H, Horna P, Walton K, Cubitt CL, Gunawan S, Lawrence HR, Lawrence NJ, Sebti SM, Anasetti C. Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function. Science Translational Medicine. 9. PMID 28077684 DOI: 10.1126/Scitranslmed.Aai8269  1
2017 Husain K, Sebti SM, Malafa MP. Abstract 1098: Delta-tocotrienol chemosensitizes human pancreatic tumor metastasis to gemcitabine targeting cancer stem cells Cancer Research. 77: 1098-1098. DOI: 10.1158/1538-7445.Am2017-1098  1
2016 Kim D, Sun M, He L, Zhou QH, Chen J, Sun XM, Bepler G, Sebti SM, Cheng JQ. A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation. The Journal of Biological Chemistry. 291: 22856. PMID 27825094 DOI: 10.1074/jbc.A109.094060  1
2016 Li H, Kuwajima T, Oakley D, Nikulina E, Hou J, Yang WS, Lowry ER, Lamas NJ, Amoroso MW, Croft GF, Hosur R, Wichterle H, Sebti S, Filbin MT, Stockwell B, et al. Protein Prenylation Constitutes an Endogenous Brake on Axonal Growth. Cell Reports. PMID 27373155 DOI: 10.1016/J.Celrep.2016.06.013  0.01
2016 Husain K, Coppola D, Sebti SM, Malafa MP. Abstract 3839: Vitamin E delta-tocotrienol targets human colon cancer stem cells and inhibits colon cancer metastasis and induces apoptosis Cancer Research. 76: 3839-3839. DOI: 10.1158/1538-7445.Am2016-3839  1
2015 Springett GM, Husain K, Neuger A, Centeno B, Chen DT, Hutchinson TZ, Lush RM, Sebti S, Malafa MP. A Phase I Safety, Pharmacokinetic, and Pharmacodynamic Presurgical Trial of Vitamin E δ-tocotrienol in Patients with Pancreatic Ductal Neoplasia. Ebiomedicine. 2: 1987-95. PMID 26844278 DOI: 10.1016/J.Ebiom.2015.11.025  1
2015 Wang C, Husain K, Zhang A, Centeno BA, Chen DT, Tong Z, Sebti SM, Malafa MP. EGR-1/Bax pathway plays a role in vitamin E δ-tocotrienol-induced apoptosis in pancreatic cancer cells. The Journal of Nutritional Biochemistry. 26: 797-807. PMID 25997867 DOI: 10.1016/J.Jnutbio.2015.02.008  1
2015 Kumar NB, Pow-Sang J, Egan KM, Spiess PE, Dickinson S, Salup R, Helal M, McLarty JW, Williams CR, Schreiber F, Parnes HL, Sebti S, Kazi A, Kang L, Quinn GP, et al. Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention. Cancer Prevention Research (Philadelphia, Pa.). PMID 25873370 DOI: 10.1158/1940-6207.Capr-14-0324  1
2015 Betts BC, Sagatys EM, Veerapathran A, Lloyd MC, Beato F, Lawrence HR, Yue B, Kim J, Sebti SM, Anasetti C, Pidala J. CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response. Journal of Leukocyte Biology. 97: 807-19. PMID 25663681 DOI: 10.1189/Jlb.5A1114-532Rr  1
2015 Li R, Cheng C, Balasis ME, Liu Y, Garner TP, Daniel KG, Li J, Qin Y, Gavathiotis E, Sebti SM. Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1/Bcl-xL inhibitors. European Journal of Medicinal Chemistry. 90: 315-31. PMID 25437618 DOI: 10.1016/J.Ejmech.2014.11.035  1
2015 Kumar NB, Pow-Sang J, Egan KM, Spiess PA, Dickinson S, Salup R, Helal M, McLarty J, Williams CR, Schreiber F, Sebti S, Kazi A, Kang L, Quinn G, Smith T, et al. Abstract PR06: Effect of polyphenon E on progression to prostate cancer after diagnosis of high grade prostatic intraepithelial neoplasia Cancer Prevention Research. 8. DOI: 10.1158/1940-6215.Prev-14-Pr06  1
2015 Husain K, Sebti SM, Malafa MP. Abstract 4383: Vitamin E delta-tocotrienol inhibits metastasis and targets cancer stem cell signaling in human pancreatic cancer Cancer Research. 75: 4383-4383. DOI: 10.1158/1538-7445.Am2015-4383  1
2015 Yang H, Emmons MF, Cubitt C, Shain K, Coppola D, Sullivan D, Lynch CC, Hazlehurst L, Sebti SM. Abstract 2605: The geranylgeranyltransferase I inhibitor GGTI-2418 suppresses multiple myeloma malignancy in the 5TMG1 mouse model Cancer Research. 75: 2605-2605. DOI: 10.1158/1538-7445.Am2015-2605  1
2015 Kennedy PC, Guilanotti MC, LsVoi T, Sebti SM. Abstract 2580: Screening of a mixture-based synthetic combinatorial library identifies small molecules that inhibit the ability of GTP to displace mant-GDP from mutant G12D KRas Cancer Research. 75: 2580-2580. DOI: 10.1158/1538-7445.Am2015-2580  0.01
2015 Berndt N, Zhang X, Jiang RHY, Sebti SM. Abstract 2153: Kinome inhibitor screen identifies kinase inhibitors that inhibit selectively the survival of mutant K-Ras-dependent human cancer cells Cancer Research. 75: 2153-2153. DOI: 10.1158/1538-7445.Am2015-2153  1
2014 Tecleab A, Zhang X, Sebti SM. Ral GTPase down-regulation stabilizes and reactivates p53 to inhibit malignant transformation. The Journal of Biological Chemistry. 289: 31296-309. PMID 25210032 DOI: 10.1074/Jbc.M114.565796  1
2014 Kim YB, Kang CW, Ranatunga S, Yang H, Sebti SM, Del Valle JR. Imidazo[1,2-a]pyridine-based peptidomimetics as inhibitors of Akt. Bioorganic & Medicinal Chemistry Letters. 24: 4650-3. PMID 25205195 DOI: 10.1016/J.Bmcl.2014.08.040  1
2014 Cheng C, Liu Y, Balasis ME, Garner TP, Li J, Simmons NL, Berndt N, Song H, Pan L, Qin Y, Nicolaou KC, Gavathiotis E, Sebti SM, Li R. Marinopyrrole derivatives with sulfide spacers as selective disruptors of Mcl-1 binding to pro-apoptotic protein Bim. Marine Drugs. 12: 4311-25. PMID 25076060 DOI: 10.3390/Md12084311  1
2014 Zhang X, Blaskovich MA, Forinash KD, Sebti SM. Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours British Journal of Cancer. 111: 894-902. PMID 24983364 DOI: 10.1038/Bjc.2014.349  1
2014 Teng P, Zhang X, Wu H, Qiao Q, Sebti SM, Cai J. Identification of novel inhibitors that disrupt STAT3-DNA interaction from a γ-AApeptide OBOC combinatorial library. Chemical Communications (Cambridge, England). 50: 8739-42. PMID 24964402 DOI: 10.1039/C4Cc03909B  1
2014 Yang H, Lawrence HR, Kazi A, Gevariya H, Patel R, Luo Y, Rix U, Schonbrunn E, Lawrence NJ, Sebti SM. Dual aurora a and jak2 kinase blockade effectively suppresses malignant transformation Oncotarget. 5: 2947-2961. PMID 24930769 DOI: 10.18632/Oncotarget.1615  1
2014 Cheng C, Liu Y, Balasis ME, Simmons NL, Li J, Song H, Pan L, Qin Y, Nicolaou KC, Sebti SM, Li R. Cyclic marinopyrrole derivatives as disruptors of Mcl-1 and Bcl-x(L) binding to Bim. Marine Drugs. 12: 1335-48. PMID 24608970 DOI: 10.3390/Md12031335  1
2014 Kazi A, Ozcan S, Tecleab A, Sun Y, Lawrence HR, Sebti SM. Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity Journal of Biological Chemistry. 289: 11906-11915. PMID 24570003 DOI: 10.1074/Jbc.M113.533950  1
2014 Patel RA, Liu Y, Wang B, Li R, Sebti SM. Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities Oncogene. 33: 550-555. PMID 23396364 DOI: 10.1038/Onc.2012.634  1
2014 Aslamuzzaman K, Zhang X, Luo Y, Patel R, Fletcher S, Cummings C, Lawrence H, Hamilton A, Sebti SM. Abstract B35: Dual inhibitors of FT and GGT-1 as novel therapeutic agents for K-Ras-dependent tumors Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-B35  1
2014 Sebti SM, Berndt N, Patel R, Yang H, Balasis M. Abstract 4522: Akt2 and acid ceramidase cooperate to induce malignant transformation Cancer Research. 74: 4522-4522. DOI: 10.1158/1538-7445.Am2014-4522  1
2014 Zhang X, Blaskovich MA, Forinash KD, Sebti SM. Abstract 3802: Withacnistin blocks binding of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumors in vivo Cancer Research. 74: 3802-3802. DOI: 10.1158/1538-7445.Am2014-3802  1
2014 Sebti SM, Kazi A, Ozcan S, Tecleab AG, Sun Y, Lawrence H. Abstract 1810: PI-1840, a novel non-covalent and rapidly reversible proteasome inhibitor with anti-tumor activity Cancer Research. 74: 1810-1810. DOI: 10.1158/1538-7445.Am2014-1810  1
2014 Sebti SM, Yang H, Lawrence H, Kazi A, Gervaria H, Patel R, Luo Y, Rix U, Schonbrunn E, Lawrence N. Abstract 1750: Combined blockade of Aurora A and JAK2 kinase is highly effective at inhibiting malignant transformation Cancer Research. 74: 1750-1750. DOI: 10.1158/1538-7445.Am2014-1750  1
2014 Husain K, Sebti SM, Malafa MP. Abstract 1699: Delta-tocotrienol potentiates the antitumor activity of standard chemotherapy with gemcitabine and abraxane in metastatic pancreatic cancer Cancer Research. 74: 1699-1699. DOI: 10.1158/1538-7445.Am2014-1699  1
2014 Blaskovich MA, Luo Y, Ge Y, Sebti SM, Lawrence HR, Lawrence NJ, Springett GM. Abstract 1640: A novel small molecule inhibitor of lysophosphatidic acid acyltransferase-beta inhibits pancreatic cancer cell proliferation and mTOR signaling Cancer Research. 74: 1640-1640. DOI: 10.1158/1538-7445.Am2014-1640  1
2013 Blaskovich MA, Yendluri V, Lawrence HR, Lawrence NJ, Sebti SM, Springett GM. Lysophosphatidic acid acyltransferase beta regulates mTOR signaling. Plos One. 8. PMID 24205284 DOI: 10.1371/Journal.Pone.0078632  1
2013 Treviño JG, Verma M, Singh S, Pillai S, Zhang D, Pernazza D, Sebti SM, Lawrence NJ, Centeno BA, Chellappan SP. Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity. Molecular Cancer Therapeutics. 12: 2722-34. PMID 24107447 DOI: 10.1158/1535-7163.Mct-12-0719  1
2013 Urlam MK, Pireddu R, Ge Y, Zhang X, Sun Y, Lawrence HR, Guida WC, Sebti SM, Lawrence NJ. Development of new N-Arylbenzamides as STAT3 Dimerization Inhibitors. Medchemcomm. 4: 932-941. PMID 24073326 DOI: 10.1039/C3Md20323A  1
2013 Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, List AF, Sebti S, Kantarjian HM, Ravandi F, Lancet JE. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leukemia Research. 37: 1461-7. PMID 23993427 DOI: 10.1016/J.Leukres.2013.07.034  1
2013 Husain K, Centeno BA, Chen DT, Hingorani SR, Sebti SM, Malafa MP. Vitamin E δ-tocotrienol prolongs survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer. Cancer Prevention Research (Philadelphia, Pa.). 6: 1074-83. PMID 23963802 DOI: 10.1158/1940-6207.Capr-13-0157  1
2013 Almhanna K, Cubitt CL, Zhang S, Kazim S, Husain K, Sullivan D, Sebti S, Malafa M. MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines. Cancer Biology & Therapy. 14: 932-6. PMID 23917345 DOI: 10.4161/Cbt.25939  1
2013 Berndt N, Patel R, Yang H, Balasis ME, Sebti SM. Akt2 and acid ceramidase cooperate to induce cell invasion and resistance to apoptosis. Cell Cycle (Georgetown, Tex.). 12: 2024-32. PMID 23777806 DOI: 10.4161/Cc.25043  1
2013 Schonbrunn E, Betzi S, Alam R, Martin MP, Becker A, Han H, Francis R, Chakrasali R, Jakkaraj S, Kazi A, Sebti SM, Cubitt CL, Gebhard AW, Hazlehurst LA, Tash JS, et al. Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases. Journal of Medicinal Chemistry. 56: 3768-82. PMID 23600925 DOI: 10.1021/Jm301234K  1
2013 Ozcan S, Kazi A, Marsilio F, Fang B, Guida WC, Koomen J, Lawrence HR, Sebti SM. Oxadiazole-isopropylamides as potent and noncovalent proteasome inhibitors Journal of Medicinal Chemistry. 56: 3783-3805. PMID 23547706 DOI: 10.1021/Jm400221D  1
2013 Hodul PJ, Dong Y, Husain K, Pimiento JM, Chen J, Zhang A, Francois R, Pledger WJ, Coppola D, Sebti SM, Chen DT, Malafa MP. Vitamin E δ-tocotrienol induces p27(Kip1)-dependent cell-cycle arrest in pancreatic cancer cells via an E2F-1-dependent mechanism. Plos One. 8: e52526. PMID 23393547 DOI: 10.1371/Journal.Pone.0052526  1
2013 Tecleab A, Sebti SM. Depletion of K-Ras promotes proteasome degradation of survivin. Cell Cycle (Georgetown, Tex.). 12: 522-32. PMID 23324341 DOI: 10.4161/Cc.23407  1
2013 Zhang X, Sun Y, Pireddu R, Yang H, Urlam MK, Lawrence HR, Guida WC, Lawrence NJ, Sebti SM. A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation Cancer Research. 73: 1922-1933. PMID 23322008 DOI: 10.1158/0008-5472.Can-12-3175  1
2013 Husain K, Centeno BA, Chen DT, Fulp WJ, Perez M, Zhang Lee G, Luetteke N, Hingorani SR, Sebti SM, Malafa MP. Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E δ-tocotrienol. Carcinogenesis. 34: 858-63. PMID 23302291 DOI: 10.1093/Carcin/Bgt002  1
2013 Ucar DA, Magis AT, He DH, Lawrence NJ, Sebti SM, Kurenova E, Zajac-Kaye M, Zhang J, Hochwald SN. Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo. Anti-Cancer Agents in Medicinal Chemistry. 13: 595-602. PMID 23272972 DOI: 10.2174/1871520611313040009  1
2013 Tecleab A, Zhang X, Sebti SM. Abstract 767: RalGTPase regulation of p53 and its contribution to malignant transformation. Cancer Research. 73: 767-767. DOI: 10.1158/1538-7445.Am2013-767  1
2013 Patel RA, Lui Y, Wang B, Li R, Sebti SM. Abstract 5556: Discovery of RKI-18, a small molecule that inhibits Rho kinases 1 and 2, migration and invasion of human tumors. Cancer Research. 73: 5556-5556. DOI: 10.1158/1538-7445.Am2013-5556  1
2013 Zhang X, Sun Y, Pireddu R, Yang H, Urlam MK, Lawrence HR, Guida WC, Lawrence NJ, Sebti SM. Abstract 3254: Discovery of S3I-1757, a STAT3-STAT3 dimerization disruptor that inhibits STAT3 activity, tumor survival, migration and invasion. Cancer Research. 73: 3254-3254. DOI: 10.1158/1538-7445.Am2013-3254  1
2013 Blaskovich MA, Gevariya H, Lawrence NJ, Sebti S, Springett G. Abstract 2470: Identification and evaluation of small molecule inhibitors of lysophosphatidic acid acyltransferase-beta. Cancer Research. 73: 2470-2470. DOI: 10.1158/1538-7445.Am2013-2470  1
2013 Lawrence NJ, Pireddu R, Ge Y, Urlam MK, Zhang X, Sun Y, Lawrence HR, Guida WC, Sebti S. Abstract 2467: Development of new N-Arylbenzamides as STAT3 dimerization inhibitors. Cancer Research. 73: 2467-2467. DOI: 10.1158/1538-7445.Am2013-2467  1
2013 Husain K, Centeno B, Perez M, Dung-Tsa C, Sebti SM, Malafa MP. Abstract 2070: Natural vitamin E delta-tocotrienol combined with gemcitabine prolongs the survival, induces apoptosis, inhibits tumor growth, angiogenesis and oncogenic signaling in a transgenic mouse model of pancreatic cancer. Cancer Research. 73: 2070-2070. DOI: 10.1158/1538-7445.Am2013-2070  1
2013 Urlam MK, Pireddu R, Ge Y, Zhang X, Sun Y, Lawrence HR, Guida WC, Sebti SM, Lawrence NJ. Development of new N-arylbenzamides as STAT3 dimerization inhibitors Medchemcomm. 4: 932-941. DOI: 10.1039/c3md20323a  1
2013 Ramananarivo HR, Solhy A, Sebti J, Smahi A, Zahouily M, Clark J, Sebti S. An eco-friendly paradigm for the synthesis of α-hydroxyphosphonates using sodium-modified fluorapatite under solventless conditions Acs Sustainable Chemistry and Engineering. 1: 403-409. DOI: 10.1021/Sc3001417  1
2012 Kumar N, Crocker T, Smith T, Connors S, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, et al. Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures. Journal of Clinical Trials. 2. PMID 24533253 DOI: 10.4172/Jctr.1000105  1
2012 Pireddu R, Forinash KD, Sun NN, Martin MP, Sung SS, Alexander B, Zhu JY, Guida WC, Schönbrunn E, Sebti SM, Lawrence NJ. Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 3: 699-709. PMID 23275831 DOI: 10.1039/C2Md00320A  1
2012 Gajewski TF, Salama AK, Niedzwiecki D, Johnson J, Linette G, Bucher C, Blaskovich MA, Sebti SM, Haluska F. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). Journal of Translational Medicine. 10: 246. PMID 23228035 DOI: 10.1200/Jco.2006.24.18_Suppl.8014  1
2012 Kim YB, Balasis ME, Doi K, Berndt N, DuBoulay C, Hu CC, Guida W, Wang HG, Sebti SM, Del Valle JR. Synthesis and evaluation of substituted hexahydronaphthalenes as novel inhibitors of the Mcl-1/BimBH3 interaction. Bioorganic & Medicinal Chemistry Letters. 22: 5961-5. PMID 22901384 DOI: 10.1016/J.Bmcl.2012.07.050  1
2012 Ucar DA, Kurenova E, Garrett TJ, Cance WG, Nyberg C, Cox A, Massoll N, Ostrov DA, Lawrence N, Sebti SM, Zajac-Kaye M, Hochwald SN. Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth. Cell Cycle (Georgetown, Tex.). 11: 3250-9. PMID 22894899 DOI: 10.1093/Carcin/Bgr115  1
2012 Patel RA, Forinash KD, Pireddu R, Sun Y, Sun N, Martin MP, Schönbrunn E, Lawrence NJ, Sebti SM. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Research. 72: 5025-34. PMID 22846914 DOI: 10.1158/0008-5472.Can-12-0954  1
2012 Lawrence HR, Martin MP, Luo Y, Pireddu R, Yang H, Gevariya H, Ozcan S, Zhu JY, Kendig R, Rodriguez M, Elias R, Cheng JQ, Sebti SM, Schonbrunn E, Lawrence NJ. Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors. Journal of Medicinal Chemistry. 55: 7392-416. PMID 22803810 DOI: 10.1021/Jm300334D  1
2012 Caceres G, Robey RW, Sokol L, McGraw KL, Clark J, Lawrence NJ, Sebti SM, Wiese M, List AF. HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1. Cancer Research. 72: 4204-13. PMID 22761337 DOI: 10.1158/0008-5472.Can-12-0743  1
2012 Cheng F, Wang H, Horna P, Wang Z, Shah B, Sahakian E, Woan KV, Villagra A, Pinilla-Ibarz J, Sebti S, Smith M, Tao J, Sotomayor EM. Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity. Cancer Research. 72: 4440-8. PMID 22728650 DOI: 10.1158/0008-5472.Can-11-3619  1
2012 Ginestier C, Monville F, Wicinski J, Cabaud O, Cervera N, Josselin E, Finetti P, Guille A, Larderet G, Viens P, Sebti S, Bertucci F, Birnbaum D, Charafe-Jauffret E. Mevalonate Metabolism Regulates Basal Breast Cancer Stem Cells and Is a Potential Therapeutic Target Stem Cells. 30: 1327-1337. PMID 22605458 DOI: 10.1002/Stem.1122  0.01
2012 Doi K, Li R, Sung SS, Wu H, Liu Y, Manieri W, Krishnegowda G, Awwad A, Dewey A, Liu X, Amin S, Cheng C, Qin Y, Schonbrunn E, Daughdrill G, ... ... Sebti S, et al. Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. The Journal of Biological Chemistry. 287: 10224-35. PMID 22311987 DOI: 10.1074/Jbc.M111.334532  1
2012 Win-Piazza H, Schneeberger VE, Chen L, Pernazza D, Lawrence HR, Sebti SM, Lawrence NJ, Wu J. Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2. Cancer Letters. 320: 81-5. PMID 22306001 DOI: 10.1016/J.Canlet.2012.01.034  1
2012 Li R, Martin MP, Liu Y, Wang B, Patel RA, Zhu JY, Sun N, Pireddu R, Lawrence NJ, Li J, Haura EB, Sung SS, Guida WC, Schonbrunn E, Sebti SM. Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors. Journal of Medicinal Chemistry. 55: 2474-8. PMID 22272748 DOI: 10.1021/Jm201289R  1
2012 Martin MP, Zhu JY, Lawrence HR, Pireddu R, Luo Y, Alam R, Ozcan S, Sebti SM, Lawrence NJ, Schönbrunn E. A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A. Acs Chemical Biology. 7: 698-706. PMID 22248356 DOI: 10.1021/Cb200508B  1
2012 Ge Y, Kazi A, Marsilio F, Luo Y, Jain S, Brooks W, Daniel KG, Guida WC, Sebti SM, Lawrence HR. Discovery and synthesis of hydronaphthoquinones as novel proteasome inhibitors. Journal of Medicinal Chemistry. 55: 1978-98. PMID 22220566 DOI: 10.1021/Jm201118H  1
2012 Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, et al. Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer. Contemporary Clinical Trials. 33: 279-85. PMID 22101219 DOI: 10.1016/J.Cct.2011.11.004  1
2012 Johnson JL, Pillai S, Pernazza D, Sebti SM, Lawrence NJ, Chellappan SP. Regulation of matrix metalloproteinase genes by E2F transcription factors: Rb-Raf-1 interaction as a novel target for metastatic disease. Cancer Research. 72: 516-26. PMID 22086850 DOI: 10.1158/0008-5472.Can-11-2647  1
2012 Bai F, Villagra AV, Zou J, Painter JS, Connolly K, Blaskovich MA, Sokol L, Sebti S, Djeu JY, Loughran TP, Wei S, Sotomayor E, Epling-Burnette P. Tipifarnib-mediated suppression of T-bet-dependent signaling pathways. Cancer Immunology, Immunotherapy : Cii. 61: 523-33. PMID 21983879 DOI: 10.1007/S00262-011-1109-0  1
2012 Pireddu R, Forinash K, Sun NN, Martin MP, Sung S, Alexander B, Zhu J, Guida WC, Schönbrunn E, Sebti SM, Lawrence NJ. Abstract 3904: Pyridylthiazole-based ureas as inhibitors of Rho-associated protein kinases Cancer Research. 72: 3904-3904. DOI: 10.1158/1538-7445.Am2012-3904  1
2012 Lawrence HR, Martin MP, Luo Y, Pireddu R, Gevariya H, Ozcan S, Zhu J, Rodriguez M, Elias R, Yang H, Sebti SM, Schonbrunn E, Lawrence NJ. Abstract 3902: Development of Aurora A inhibitors withortho-halophenyl substituted pyrimidines: Unusual potency, SAR and X-ray crystallography studies. Cancer Research. 72: 3902-3902. DOI: 10.1158/1538-7445.Am2012-3902  1
2012 Ozcan S, Kazi A, Sun NN, Daniel K, Guida WC, Lawrence HR, Sebti SM. Abstract 3894: Discovery, synthesis and SAR studies of a novel nonpeptidic reversible proteosome inhibitor with low nano-molar chymotrypsin like activity Cancer Research. 72: 3894-3894. DOI: 10.1158/1538-7445.Am2012-3894  1
2012 Patel RA, Forinash KD, Pireddu R, Sun Y, Martin MP, Zhu J, Alexander BG, Schonbrunn E, Lawrence NJ, Sebti SM. Abstract 2942: RKI-1447, a potent ROCK inhibitor with anti-tumor and anti-invasive activities in breast cancer Cancer Research. 72: 2942-2942. DOI: 10.1158/1538-7445.Am2012-2942  1
2012 Ge Y, Lawrence HR, Chen L, Scott LM, Sebti SM, Lawrence NJ, Wu J. Abstract 2912: Development of potent SHP2 inhibitors forin vivostudies Cancer Research. 72: 2912-2912. DOI: 10.1158/1538-7445.Am2012-2912  1
2012 Kazi A, Ozcan S, Lawrence H, Sebti SM. Abstract 2778: Development of non-covalent reversible proteasome inhibitors Cancer Research. 72: 2778-2778. DOI: 10.1158/1538-7445.Am2012-2778  1
2012 Blaskovich M, Gevariya H, Lawrence NJ, Sebti SM, Springett G. Abstract 1854: Lysophosphatidic Acid Acyltransferase-Beta contributes to proliferation and anchorage-independent growth in pancreatic adenocarcinoma Cancer Research. 72: 1854-1854. DOI: 10.1158/1538-7445.Am2012-1854  1
2012 Husain K, Centeno B, Perez M, Lee G, Kazim S, Chen D, Sebti S, Malafa M. Abstract 1613: Delta-tocotrienol delays the progression of pancreatic intraepithelial neoplasia (PanIN) lesions in a conditional KrasG12D mouse model Cancer Research. 72: 1613-1613. DOI: 10.1158/1538-7445.Am2012-1613  1
2012 Dakkach M, Atlamsani A, Sebti S. Le phosphate naturel modifié au vanadium : un nouveau catalyseur pour l’oxydation des cycloalcanones et des α-cétols en présence de l’oxygène moléculaire Comptes Rendus Chimie. 15: 482-492. DOI: 10.1016/J.Crci.2012.03.003  0.01
2011 Berndt N, Sebti SM. Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors. Nature Protocols. 6: 1775-91. PMID 22036881 DOI: 10.1038/Nprot.2011.387  1
2011 Berndt N, Hamilton AD, Sebti SM. Targeting protein prenylation for cancer therapy. Nature Reviews. Cancer. 11: 775-91. PMID 22020205 DOI: 10.1038/Nrc3151  1
2011 Husain K, Francois RA, Yamauchi T, Perez M, Sebti SM, Malafa MP. Vitamin E δ-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-κB activation in pancreatic cancer. Molecular Cancer Therapeutics. 10: 2363-72. PMID 21971120 DOI: 10.1158/1535-7163.Mct-11-0424  1
2011 Balasis ME, Forinash KD, Chen YA, Fulp WJ, Coppola D, Hamilton AD, Cheng JQ, Sebti SM. Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2852-62. PMID 21536547 DOI: 10.1158/1078-0432.Ccr-10-2544  1
2011 O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, Kazi A, Moore DT, Learoyd M, Lush RM, Sebti SM, Sullivan DM. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2350-6. PMID 21519015 DOI: 10.1200/Jco.2010.33.9432  1
2011 Hu Y, Li X, Sebti SM, Chen J, Cai J. Design and synthesis of AApeptides: a new class of peptide mimics. Bioorganic & Medicinal Chemistry Letters. 21: 1469-71. PMID 21292484 DOI: 10.1016/J.Bmcl.2011.01.005  1
2011 Lancet JE, Duong VH, Winton EF, Stuart RK, Burton M, Zhang S, Cubitt C, Blaskovich MA, Wright JJ, Sebti S, Sullivan DM. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1140-6. PMID 21233404 DOI: 10.1158/1078-0432.Ccr-10-1878  1
2011 Scott LM, Chen L, Daniel KG, Brooks WH, Guida WC, Lawrence HR, Sebti SM, Lawrence NJ, Wu J. Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs. Bioorganic & Medicinal Chemistry Letters. 21: 730-3. PMID 21193311 DOI: 10.1016/J.Bmcl.2010.11.117  1
2011 Kazi A, Sun J, Doi K, Sung SS, Takahashi Y, Yin H, Rodriguez JM, Becerril J, Berndt N, Hamilton AD, Wang HG, Sebti SM. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner. The Journal of Biological Chemistry. 286: 9382-92. PMID 21148306 DOI: 10.1074/Jbc.M110.203638  1
2011 Garrett CR, Coppola D, Wenham RM, Cubitt CL, Neuger AM, Frost TJ, Lush RM, Sullivan DM, Cheng JQ, Sebti SM. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Investigational New Drugs. 29: 1381-9. PMID 20644979 DOI: 10.1007/S10637-010-9479-2  1
2011 Kazi A, Luo Y, Berndt N, Fletcher S, Cummings C, Lawrence H, Hamilton AD, Sebti SM. Abstract 620: Development of a dual protein farnesyltransferase -geranylgeranyltransferase-I inhibitor with antitumor activity against human cancer cells Cancer Research. 71: 620-620. DOI: 10.1158/1538-7445.Am2011-620  1
2011 Tecleab A, Sebti SM. Abstract 3844: K-Ras is required for maintaining survivin protein stability in human cancer cells harboring mutant but not wild type K-Ras Cancer Research. 71: 3844-3844. DOI: 10.1158/1538-7445.Am2011-3844  1
2011 Pireddu R, Lawrence HR, Martin MP, Betzi S, Yip R, Yang H, Sun NN, Cheng JQ, Schonbrunn E, Sebti SM, Lawrence NJ. Abstract 3253: Novel oxindole inhibitors of Aurora A kinase: Structure based hit-to-lead approach Cancer Research. 71: 3253-3253. DOI: 10.1158/1538-7445.Am2011-3253  1
2011 Luo Y, Martin M, Kendig R, Pireddu R, Yang H, Betzi S, Books W, Yu H, Schonbrunn E, Lawrence N, Cheng J, Sebti S, Lawrence H. Abstract 3252: Potent Aurora kinase inhibitors based on a pyrimidine scaffold: Synthesis, SAR and X-ray crystallography studies Cancer Research. 71: 3252-3252. DOI: 10.1158/1538-7445.Am2011-3252  1
2011 Gevariya H, Ortiz ED, Chen L, Daniel K, Lawrence HR, Guida WC, Sebti SM, Wu J, Lawrence NJ. Abstract 3248: New inhibitors of the Shp2 phosphatase Cancer Research. 71: 3248-3248. DOI: 10.1158/1538-7445.Am2011-3248  1
2011 Alexander BG, Pireddu R, Sun NN, Yu H, Forinash KD, Martin MP, Schonbrunn E, Guida WC, Sebti SM, Lawrence NJ. Abstract 3243: Discovery of novel Rho kinase inhibitors: Hit generation and lead optimization Cancer Research. 71: 3243-3243. DOI: 10.1158/1538-7445.Am2011-3243  1
2011 Pernazza D, Li X, Lawrence HR, Guida WC, DuBoulay CJ, Watts S, Sebti SM, Chen J, Lawrence NJ. Abstract 3242: New chemical tools for disrupting the MDM2/p53 protein-protein interaction: Identification, synthesis and biological evaluation of a novel class of MDM2/p53 inhibitors Cancer Research. 71: 3242-3242. DOI: 10.1158/1538-7445.Am2011-3242  1
2011 Scott LM, Chen L, Daniel KG, Urlam MK, Brooks WH, Guida WC, Lawrence HR, Sebti SM, Lawrence NJ, Wu J. Abstract 3239: Shp2 inhibitor activity of estramustine phosphate and its triterpenoid analogues Cancer Research. 71: 3239-3239. DOI: 10.1158/1538-7445.Am2011-3239  1
2011 Treviño JG, Verma M, Singh S, Pireddu R, Sebti S, Lawrence N, Chellappan SP. Abstract 2590: Selective disruption of Rb-Raf-1 kinase interaction is a suitable therapeutic option for pancreatic adenocarcinoma Cancer Research. 71: 2590-2590. DOI: 10.1158/1538-7445.Am2011-2590  1
2011 Verma M, Johnson J, Kovacs M, Singh S, Wu X, Lawrence N, Sebti S, Chellappan S. Abstract 2108: New analogues of benzyl-isothiourea showed Rb-Raf disruption and anti-cancer activity Cancer Research. 71: 2108-2108. DOI: 10.1158/1538-7445.Am2011-2108  1
2011 Blaskovich MA, Coppola D, Helm J, Sebti S, Springett GM. Abstract 1677: Expression of lysophosphatidic acid acyltransferase-beta in human pancreatic ductal adenocarcinoma Cancer Research. 71: 1677-1677. DOI: 10.1158/1538-7445.Am2011-1677  1
2011 Husain K, Coppola D, Centeno B, Helm R, Dung-Tsa C, Sebti S, Malafa M. Abstract 1667: In vitro and in vivo validation of CSE1L/hCAS as a potential molecular target in pancreatic cancer Cancer Research. 71: 1667-1667. DOI: 10.1158/1538-7445.Am2011-1667  1
2011 Ge Y, Ozcan S, Kazi A, Marsilio F, Daniel K, Brooks W, Guida W, Lawrence H, Sebti S. Abstract 1362: Discovery of a novel structural class of compounds: HLM-030376 and its analogs as potent chymotrypsin-like proteasome inhibitors Cancer Research. 71: 1362-1362. DOI: 10.1158/1538-7445.Am2011-1362  1
2011 Ozcan S, Aslamuzzaman K, Marsilio F, Daniel K, Brooks W, Guida W, Lawrence H, Sebti S. Abstract 1359: Identification of a novel class of compounds as proteasome inhibitors: Synthesis and structure activity relationship studies of PI-1833 library Cancer Research. 71: 1359-1359. DOI: 10.1158/1538-7445.Am2011-1359  1
2011 Pernazza D, Doi K, Lawrence H, Sebti S, Wang H, Lawrence N. Abstract 1354: New chemical tools for disrupting the Mcl-1/BH3 protein-protein interaction Cancer Research. 71: 1354-1354. DOI: 10.1158/1538-7445.Am2011-1354  1
2011 Springett GM, Neuger AM, Centeno BA, Hutchinson T, Jump H, Lush R, Sebti S, Malafa MP. Abstract 1299: A phase I dose-escalation study of the safety, PK, and PD of vitamin E Δ-tocotrienol administered to subjects with resectable pancreatic exocrine neoplasia Cancer Research. 71: 1299-1299. DOI: 10.1158/1538-7445.Am2011-1299  1
2011 Liu Y, Wang B, Patel RA, Sun N, Sung S, Pireddu R, Lawrence NJ, Sebti SM, Li R. Abstract A130: Fragment-based discovery and optimization of Rho kinase inhibitors. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A130  1
2011 Berndt N, Hamilton AD, Sebti SM. Geranylgeranyltransferase-1 Inhibitors Enzymes. 30: 129-163. DOI: 10.1016/B978-0-12-415922-8.00006-9  1
2010 Singh S, Davis R, Alamanda V, Pireddu R, Pernazza D, Sebti S, Lawrence N, Chellappan S. Rb-Raf-1 interaction disruptor RRD-251 induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine. Molecular Cancer Therapeutics. 9: 3330-41. PMID 21139044 DOI: 10.1158/1535-7163.Mct-10-0442  1
2010 Fletcher S, Keaney EP, Cummings CG, Blaskovich MA, Hast MA, Glenn MP, Chang SY, Bucher CJ, Floyd RJ, Katt WP, Gelb MH, Van Voorhis WC, Beese LS, Sebti SM, Hamilton AD. Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents. Journal of Medicinal Chemistry. 53: 6867-88. PMID 20822181 DOI: 10.1021/Jm1001748  1
2010 Lawrence HR, Kazi A, Luo Y, Kendig R, Ge Y, Jain S, Daniel K, Santiago D, Guida WC, Sebti SM. Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors. Bioorganic & Medicinal Chemistry. 18: 5576-92. PMID 20621484 DOI: 10.1016/J.Bmc.2010.06.038  1
2010 Chen L, Pernazza D, Scott LM, Lawrence HR, Ren Y, Luo Y, Wu X, Sung SS, Guida WC, Sebti SM, Lawrence NJ, Wu J. Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112. Biochemical Pharmacology. 80: 801-10. PMID 20510203 DOI: 10.1016/J.Bcp.2010.05.019  1
2010 Scott LM, Lawrence HR, Sebti SM, Lawrence NJ, Wu J. Targeting protein tyrosine phosphatases for anticancer drug discovery Current Pharmaceutical Design. 16: 1843-1862. PMID 20337577 DOI: 10.2174/138161210791209027  1
2010 Mahajan K, Coppola D, Challa S, Fang B, Chen YA, Zhu W, Lopez AS, Koomen J, Engelman RW, Rivera C, Muraoka-Cook RS, Cheng JQ, Schönbrunn E, Sebti SM, Earp HS, et al. Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. Plos One. 5: e9646. PMID 20333297 DOI: 10.1371/Journal.Pone.0009646  1
2010 Kim D, Sun M, He L, Zhou QH, Chen J, Sun XM, Bepler G, Sebti SM, Cheng JQ. A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation. The Journal of Biological Chemistry. 285: 8383-94. PMID 20068047 DOI: 10.1074/Jbc.M109.094060  1
2010 Phan J, Li Z, Kasprzak A, Li B, Sebti S, Guida W, Schönbrunn E, Chen J. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX. The Journal of Biological Chemistry. 285: 2174-83. PMID 19910468 DOI: 10.1074/Jbc.M109.073056  1
2010 Solhy A, Sebti S, Tahir R, Sebti J, Ould Abba M, Bousmina M, Vaudreuil S, Zahouily M. Remarkable catalytic activity of sodium-modified-hydroxyapatite in the synthesis of α-hydroxyphosphonates Current Organic Chemistry. 14: 1517-1522. DOI: 10.2174/138527210791616821  1
2010 Caceres G, Robey RW, Sokol L, McGraw KR, Fulp WJ, Clark J, Lawrence NJ, Sebti S, Bates SE, List AF. In Vitro and In Vivo Inhibition of P-Glycoprotein (ABCB1) by a Novel Non-Substrate Compound: HG-829 Blood. 116: 3986-3986. DOI: 10.1182/Blood.V116.21.3986.3986  1
2010 Lawrence HR, Chen L, Pernazza D, Scott L, Ren Y, Luo Y, Wu X, Shen-Shu S, Guida W, Sebti SM, Lawrence NJ, Wu J. Abstract 761: The development of cell permeable Shp2 PTP inhibitors Cancer Research. 70: 761-761. DOI: 10.1158/1538-7445.Am10-761  1
2010 Wu X, Scott L, Chen L, Lawrence HR, Luo Y, Sebti SM, Wu J, Lawrence NJ. Abstract 734: Development of small molecule inhibitors of the phosphatase Shp2 by fragment screening Cancer Research. 70: 734-734. DOI: 10.1158/1538-7445.Am10-734  1
2010 Pireddu R, Sun NN, Yu H, Sung S, Sebti SM, Lawrence NJ. Abstract 733: Synthesis and biological evaluation of inhibitors of Rho protein kinase Cancer Research. 70: 733-733. DOI: 10.1158/1538-7445.Am10-733  1
2010 Pernazza D, Lawrence HR, Doi K, Sung S, Guida WC, Sebti SM, Wang H, Lawrence NJ. Abstract 732: Targeting the Bcl-2/BH3 protein-protein interaction: Identification, design, and synthesis of new selective inhibitors of the Mcl-1/BH3 interaction Cancer Research. 70: 732-732. DOI: 10.1158/1538-7445.Am10-732  1
2010 Husain K, Perez M, Sebti S, Malafa M. Abstract 5416: Delta-tocotrienol potentiates antitumor activity of gemcitabine in pancreatic cancer through inhibition of nuclear factor-κB Cancer Research. 70: 5416-5416. DOI: 10.1158/1538-7445.Am10-5416  1
2010 Berndt N, Yang H, Trinczek B, Zhang Z, Wu B, Lawrence NJ, Pellechia M, Schonbrunn E, Cheng JQ, Sebti SM. Abstract 3680: The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane Cancer Research. 70: 3680-3680. DOI: 10.1158/1538-7445.Am10-3680  1
2010 Yang H, Wang D, Hamilton AD, Sebti SM. Abstract 3675: Farnesyltransferase inhibitor (FTI) disruption of Rheb/FKBP38 association leads to FKBP38-mediated inactivation of mTOR Cancer Research. 70: 3675-3675. DOI: 10.1158/1538-7445.Am10-3675  1
2010 Zhang A, Francois RA, Hodul PJ, Husain K, Shivers SC, Coppola D, Sebti SM, Malafa MP. Abstract 222: Inhibition of cellular FLICE-inhibitory protein and induction of death receptor 5 expression is a major component of δ-tocotrienol-induced apoptosis in pancreatic cancer cells Cancer Research. 70: 222-222. DOI: 10.1158/1538-7445.Am10-222  1
2010 Husain K, Coppola D, Centeno B, Helm J, Kooman J, Lawrence N, Sebti S, Malafa M. Abstract 1612: Validation of CSE1L/hCAS as a potential therapeutic target in pancreatic cancer Cancer Research. 70: 1612-1612. DOI: 10.1158/1538-7445.Am10-1612  1
2010 Solhy A, Tahir R, Sebti S, Skouta R, Bousmina M, Zahouily M, Larzek M. Efficient synthesis of chalcone derivatives catalyzed by re-usable hydroxyapatite Applied Catalysis a: General. 374: 189-193. DOI: 10.1016/J.Apcata.2009.12.008  1
2009 O'Neil BH, Williams-Goff LW, Kauh J, Bekaii-Saab T, Strosberg JR, Lee R, Deal AM, Sullivan D, Sebti SM. A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e15574. PMID 27962385 DOI: 10.1200/Jco.2009.27.15_Suppl.E15574  0.01
2009 Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF, Moulder S, Wheler JJ, Naing A, Tannir NM, Ng CS, Sherman SI, El Naggar AK, Khan R, Trent J, et al. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7061-8. PMID 19903778 DOI: 10.1158/1078-0432.Ccr-09-1241  1
2009 Kazi A, Lawrence H, Guida WC, McLaughlin ML, Springett GM, Berndt N, Yip RM, Sebti SM. Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells. Cell Cycle (Georgetown, Tex.). 8: 1940-51. PMID 19471122 DOI: 10.4161/Cc.8.12.8798  1
2009 Lawrence HR, Li Z, Yip ML, Sung SS, Lawrence NJ, McLaughlin ML, McManus GJ, Zaworotko MJ, Sebti SM, Chen J, Guida WC. Identification of a disruptor of the MDM2-p53 protein-protein interaction facilitated by high-throughput in silico docking. Bioorganic & Medicinal Chemistry Letters. 19: 3756-9. PMID 19457663 DOI: 10.1016/J.Bmcl.2009.04.124  1
2009 Sparano JA, Moulder S, Kazi A, Coppola D, Negassa A, Vahdat L, Li T, Pellegrino C, Fineberg S, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, ... ... Sebti SM, et al. Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 2942-8. PMID 19351752 DOI: 10.1158/1078-0432.Ccr-08-2658  1
2009 Hast MA, Fletcher S, Cummings CG, Pusateri EE, Blaskovich MA, Rivas K, Gelb MH, Van Voorhis WC, Sebti SM, Hamilton AD, Beese LS. Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase. Chemistry & Biology. 16: 181-92. PMID 19246009 DOI: 10.1016/J.Chembiol.2009.01.014  1
2009 Kazi A, Carie A, Blaskovich MA, Bucher C, Thai V, Moulder S, Peng H, Carrico D, Pusateri E, Pledger WJ, Berndt N, Hamilton A, Sebti SM. Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy. Molecular and Cellular Biology. 29: 2254-63. PMID 19204084 DOI: 10.1128/Mcb.01029-08  1
2009 Kayser-Bricker KJ, Glenn MP, Lee SH, Sebti SM, Cheng JQ, Hamilton AD. Non-peptidic substrate-mimetic inhibitors of Akt as potential anti-cancer agents. Bioorganic & Medicinal Chemistry. 17: 1764-71. PMID 19179081 DOI: 10.1016/J.Bmc.2008.09.058  1
2009 Husain K, Francois RA, Hutchinson SZ, Neuger AM, Lush R, Coppola D, Sebti S, Malafa MP. Vitamin E δ-Tocotrienol Levels in Tumor and Pancreatic Tissue of Mice after Oral Administration Pharmacology. 83: 157-163. PMID 19142032 DOI: 10.1159/000190792  1
2009 Siddiquee KAZ, Gunning PT, Glenn M, Katt WP, Zhang S, Schrock C, Sebti SM, Jove R, Hamilton AD, Turkson J. An oxazole-based small-molecule stat3 inhibitor modulates stat3 stability and processing and induces antitumor cell effects (ACS Chemical Biology (2007) 2, (787-798)) Acs Chemical Biology. 4: 309. DOI: 10.1021/Cb9000684  1
2008 Chintala L, Kurzrock R, Fu S, Naing A, Wheler JJ, Moulder SL, Newman R, Gagel R, Sebti S, Wright JJ, Hong DS. Phase I study of tipifarnib and sorafenib in patients with biopsiable advanced cancer (NCI protocol 7156). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3593. PMID 27949369 DOI: 10.1200/Jco.2008.26.15_Suppl.3593  1
2008 Gunning PT, Glenn MP, Siddiquee KA, Katt WP, Masson E, Sebti SM, Turkson J, Hamilton AD. Targeting protein-protein interactions: suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders. Chembiochem : a European Journal of Chemical Biology. 9: 2800-3. PMID 19006150 DOI: 10.1002/Cbic.200800291  1
2008 Epling-Burnette PK, Sokol L, Chen X, Bai F, Zhou J, Blaskovich MA, Zou J, Painter JS, Edwards TD, Moscinski L, Yoder JA, Djeu JY, Sebti S, Loughran TP, Wei S. Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood. 112: 4694-8. PMID 18791165 DOI: 10.1182/Blood-2008-02-136382  1
2008 Fletcher S, Cummings CG, Rivas K, Katt WP, Hornéy C, Buckner FS, Chakrabarti D, Sebti SM, Gelb MH, Van Voorhis WC, Hamilton AD. Potent, Plasmodium-selective farnesyltransferase inhibitors that arrest the growth of malaria parasites: structure-activity relationships of ethylenediamine-analogue scaffolds and homology model validation. Journal of Medicinal Chemistry. 51: 5176-97. PMID 18686940 DOI: 10.1021/Jm800113P  1
2008 Lawrence HR, Pireddu R, Chen L, Luo Y, Sung SS, Szymanski AM, Yip ML, Guida WC, Sebti SM, Wu J, Lawrence NJ. Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. Journal of Medicinal Chemistry. 51: 4948-56. PMID 18680359 DOI: 10.1021/Jm8002526  1
2008 Gustafsdottir SM, Wennström S, Fredriksson S, Schallmeiner E, Hamilton AD, Sebti SM, Landegren U. Use of proximity ligation to screen for inhibitors of interactions between vascular endothelial growth factor A and its receptors. Clinical Chemistry. 54: 1218-25. PMID 18499900 DOI: 10.1373/Clinchem.2007.099424  1
2008 Kinkade R, Dasgupta P, Carie A, Pernazza D, Carless M, Pillai S, Lawrence N, Sebti SM, Chellappan S. A small molecule disruptor of Rb/Raf-1 interaction inhibits cell proliferation, angiogenesis, and growth of human tumor xenografts in nude mice. Cancer Research. 68: 3810-8. PMID 18483265 DOI: 10.1158/0008-5472.Can-07-6672  1
2008 Kurzrock R, Kantarjian HM, Blascovich MA, Bucher C, Verstovsek S, Wright JJ, Pilat SR, Cortes JE, Estey EH, Giles FJ, Beran M, Sebti SM. Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 509-14. PMID 18223226 DOI: 10.1158/1078-0432.Ccr-07-1532  1
2008 Machida S, Usuba K, Blaskovich MA, Yano A, Harada K, Sebti SM, Kato N, Ohkanda J. Module assembly for protein-surface recognition: geranylgeranyltransferase I bivalent inhibitors for simultaneous targeting of interior and exterior protein surfaces. Chemistry (Weinheim An Der Bergstrasse, Germany). 14: 1392-401. PMID 18200641 DOI: 10.1002/Chem.200701634  1
2008 Elahi A, Zhang L, Yeatman TJ, Gery S, Sebti S, Shibata D. HPP1-mediated tumor suppression requires activation of STAT1 pathways. International Journal of Cancer. Journal International Du Cancer. 122: 1567-72. PMID 18059030 DOI: 10.1002/Ijc.23202  1
2008 Ravandi F, Sampath D, Plunkett W, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, Alvarez V, Becker MD, List AF, Sebti S, Kantarjian HM, Lancet J. Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy Blood. 112: 2987-2987. DOI: 10.1182/Blood.V112.11.2987.2987  1
2008 Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, Sebti SM. Cucurbitacin Q: A selective STAT3 activation inhibitor with potent antitumor activity (Oncogene (2005) 24, (3236-3245) DOI: 10.1038/sj.onc.1208470) ) Oncogene. 27: 1344. DOI: 10.1038/sj.onc.1211028  1
2008 Smahi A, Solhy A, Tahir R, Sebti S, Mayoral JA, García JI, Fraile JM, Zahouily M. Preparation of α-hydroxyphosphonates over phosphate catalysts Catalysis Communications. 9: 2503-2508. DOI: 10.1016/J.Catcom.2008.07.005  0.01
2007 Siddiquee KA, Gunning PT, Glenn M, Katt WP, Zhang S, Schrock C, Schroeck C, Sebti SM, Jove R, Hamilton AD, Turkson J. An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. Acs Chemical Biology. 2: 787-98. PMID 18154266 DOI: 10.1021/Cb7001973  1
2007 Saglam O, Garrett CR, Boulware D, Sayegh Z, Shibata D, Malafa M, Yeatman T, Cheng JQ, Sebti S, Coppola D. Activation of the serine/threonine protein kinase AKT during the progression of colorectal neoplasia. Clinical Colorectal Cancer. 6: 652-6. PMID 17945038 DOI: 10.3816/Ccc.2007.N.034  1
2007 Falsetti SC, Wang DA, Peng H, Carrico D, Cox AD, Der CJ, Hamilton AD, Sebti SM. Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth. Molecular and Cellular Biology. 27: 8003-14. PMID 17875936 DOI: 10.1128/Mcb.00057-07  1
2007 Sagatys E, Garrett CR, Boulware D, Kelley S, Malafa M, Cheng JQ, Sebti S, Coppola D. Activation of the serine/threonine protein kinase Akt during the progression of Barrett neoplasia. Human Pathology. 38: 1526-31. PMID 17640711 DOI: 10.1016/J.Humpath.2007.03.003  1
2007 Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, Yip ML, Jove R, McLaughlin MM, Lawrence NJ, Sebti SM, Turkson J. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proceedings of the National Academy of Sciences of the United States of America. 104: 7391-6. PMID 17463090 DOI: 10.1073/Pnas.0609757104  1
2007 Gunning PT, Katt WP, Glenn M, Siddiquee K, Siddique K, Kim JS, Jove R, Sebti SM, Turkson J, Hamilton AD. Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains. Bioorganic & Medicinal Chemistry Letters. 17: 1875-8. PMID 17336521 DOI: 10.1016/J.Bmcl.2007.01.077  1
2007 Epifano F, Curini M, Genovese S, Blaskovich M, Hamilton A, Sebti SM. Prenyloxyphenylpropanoids as novel lead compounds for the selective inhibition of geranylgeranyl transferase I Bioorganic and Medicinal Chemistry Letters. 17: 2639-2642. PMID 17314046 DOI: 10.1016/J.Bmcl.2007.01.097  1
2007 Kayser KJ, Glenn MP, Sebti SM, Cheng JQ, Hamilton AD. Modifications of the GSK3beta substrate sequence to produce substrate-mimetic inhibitors of Akt as potential anti-cancer therapeutics. Bioorganic & Medicinal Chemistry Letters. 17: 2068-73. PMID 17276059 DOI: 10.1016/J.Bmcl.2007.01.004  1
2007 Carie AE, Sebti SM. A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene. 26: 3777-88. PMID 17260025 DOI: 10.1038/Sj.Onc.1210172  1
2007 Epling-Burnette PK, Sokol L, Moscinski L, Elkabani M, Bai F, Blaskovich M, Zou J, Painter JS, Sebti S, Loughran TP. First Clinical Report of Tipifarnib for the Treatment of T-Large Granular Lymphocyte (LGL) Leukemia. Blood. 110: 3132-3132. DOI: 10.1182/Blood.V110.11.3132.3132  1
2007 Wang H, Cheng F, Noyes D, Wright K, Mohapatra S, Tao J, Schell M, Sebti S, Smith M, Bhalla K, Pinilla J, Dessureault S, Celis D, Sotomayor EM, Sotomayor IbEM. Enhancement of the Antigen-Presenting Cell Function of Mantle Cell Lymphomas (MCL) by Novel Molecularly Based Immunotherapeutic Strategies. Blood. 110: 2315-2315. DOI: 10.1182/Blood.V110.11.2315.2315  0.01
2007 Bai F, Zou J-, Wei S, Painter JS, Blaskovich M, Sebti S, Loughran TP, Epling-Burnette PK. Th2 Polarization Induced by the Farnesyltransferase Inhibitor Tipifarnib (Zarnestra®, R115777) through Suppression of T-bet. Blood. 110: 1331-1331. DOI: 10.1182/Blood.V110.11.1331.1331  1
2007 Zahouily M, Mounir B, Cherki H, Bahlaouan B, Rayadh A, Sebti S. Natural Phosphate Modified with Lithium Nitrate: A New Efficient Catalyst for the Construction of Carbon–Carbon, Carbon–Sulfur, and Carbon–Nitrogen Bonds Phosphorus Sulfur and Silicon and the Related Elements. 182: 1203-1217. DOI: 10.1080/10426500601160397  0.01
2007 Zahouily M, Elmakssoudi A, Mezdar A, Rayadh A, Sebti S. Natural phosphate and potassium fluoride doped natural phosphate catalysed simple one-pot synthesis of α-amino phosphonates under solvent-free conditions at room temperature Catalysis Communications. 8: 225-230. DOI: 10.1016/J.Catcom.2006.06.017  0.01
2007 Epifano F, Curini M, Genovese S, Blaskovich M, Hamilton A, Sebti SM. Corrigendum to "Prenyloxyphenylpropanoids as novel lead compounds for the selective inhibition of geranylgeranyl transferase I" [Bioorg. Med. Chem. Lett. 17 (2007) 2639-2642] (DOI:10.1016/j.bmcl.2007.01.097) Bioorganic and Medicinal Chemistry Letters. 17: 5492. DOI: 10.1016/J.Bmcl.2007.07.042  1
2007 Gunning PT, Katt WP, Glenn M, Siddiquee K, Kim JS, Jove R, Sebti SM, Turkson J, Hamilton AD. Corrigendum to "Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: Structural recognition of STAT SH2 domains" [Bioorg. Med. Chem. Lett. 17 (2007) 1875-1878] (DOI:10.1016/j.bmcl.2007.01.077) Bioorganic and Medicinal Chemistry Letters. 17: 2949. DOI: 10.1016/J.Bmcl.2007.03.063  1
2006 Glenn MP, Chang SY, Hornéy C, Rivas K, Yokoyama K, Pusateri EE, Fletcher S, Cummings CG, Buckner FS, Pendyala PR, Chakrabarti D, Sebti SM, Gelb M, Van Voorhis WC, Hamilton AD. Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. Journal of Medicinal Chemistry. 49: 5710-27. PMID 16970397 DOI: 10.1021/Jm060081V  1
2006 Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. The Journal of Biological Chemistry. 281: 33030-5. PMID 16905541 DOI: 10.1074/Jbc.C600147200  1
2006 Sparano JA, Moulder S, Kazi A, Vahdat L, Li T, Pellegrino C, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Sebti SM. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 3013-8. PMID 16769985 DOI: 10.1200/Jco.2005.04.9114  1
2006 Zhou H, Wang DA, Baldini L, Ennis E, Jain R, Carie A, Sebti SM, Hamilton AD. Structure-activity studies on a library of potent calix[4]arene-based PDGF antagonists that inhibit PDGF-stimulated PDGFR tyrosine phosphorylation. Organic & Biomolecular Chemistry. 4: 2376-86. PMID 16763682 DOI: 10.1039/B515483A  1
2006 Tang D, Park HJ, Georgescu SP, Sebti SM, Hamilton AD, Galper JB. Simvastatin potentiates tumor necrosis factor alpha-mediated apoptosis of human vascular endothelial cells via the inhibition of the geranylgeranylation of RhoA. Life Sciences. 79: 1484-92. PMID 16740276 DOI: 10.1016/J.Lfs.2006.04.019  1
2006 Chen L, Sung SS, Yip ML, Lawrence HR, Ren Y, Guida WC, Sebti SM, Lawrence NJ, Wu J. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Molecular Pharmacology. 70: 562-70. PMID 16717135 DOI: 10.1124/Mol.106.025536  1
2006 Peng H, Carrico D, Thai V, Blaskovich M, Bucher C, Pusateri EE, Sebti SM, Hamilton AD. Synthesis and evaluation of potent, highly-selective, 3-aryl-piperazinone inhibitors of protein geranylgeranyltransferase-I. Organic & Biomolecular Chemistry. 4: 1768-84. PMID 16633570 DOI: 10.1039/B517572K  1
2006 Donapaty S, Louis S, Horvath E, Kun J, Sebti SM, Malafa MP. RRR-alpha-tocopherol succinate down-regulates oncogenic Ras signaling. Molecular Cancer Therapeutics. 5: 309-16. PMID 16505104 DOI: 10.1158/1535-7163.Mct-05-0330  1
2006 Ohkanda J, Strickland CL, Blaskovich MA, Carrico D, Lockman JW, Vogt A, Bucher CJ, Sun J, Qian Y, Knowles D, Pusateri EE, Sebti SM, Hamilton AD. Structure-based design of imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase. Organic & Biomolecular Chemistry. 4: 482-92. PMID 16446806 DOI: 10.1039/B508184J  1
2006 Zahouily M, Bahlaouan B, Abrouki Y, Salah M, Bahlaouan O, Rayadh A, Aadil M, Sebti S. Natural Phosphate and Potassium Fluoride Doped Natural Phosphate as New Catalysts for the Vilsmeir–Haack type Reaction Journal of Chemical Research-S. 2006: 34-36. DOI: 10.3184/030823406776331043  0.01
2006 Bazi F, Badaoui HE, Sokori S, Tamani S, Hamza M, Boulaajaj S, Sebti S. Transesterification of Methylbenzoate with Alcohols Catalyzed by Natural Phosphate Synthetic Communications. 36: 1585-1592. DOI: 10.1080/00397910600591508  0.01
2006 Bazi F, Badaoui HE, Tamani S, Sokori S, Oubella L, Hamza M, Boulaajaj S, Sebti S. Catalysis by phosphates: A simple and efficient procedure for transesterification reaction Journal of Molecular Catalysis a-Chemical. 256: 43-47. DOI: 10.1016/J.Molcata.2006.04.034  0.01
2006 Bazi F, Badaoui HE, Tamani S, Sokori S, Solhy A, Macquarrie DJ, Sebti S. A facile synthesis of amides by selective hydration of nitriles using modified natural phosphate and hydroxyapatite as new catalysts Applied Catalysis a-General. 301: 211-214. DOI: 10.1016/J.Apcata.2005.12.003  0.01
2005 Guida WC, Hamilton AD, Crotty JW, Sebti SM. Protein farnesyltransferase: flexible docking studies on inhibitors using computational modeling. Journal of Computer-Aided Molecular Design. 19: 871-85. PMID 16607571 DOI: 10.1007/S10822-005-9030-2  1
2005 Lazrek HB, Taourirte M, Rochdi A, Redwane N, Ouzebla D, Baddi L, Sebti S, Vasseur JJ. Natural phosphate doped with KI in HMDS: a mild and efficient reagent for alkylation and glycosylation of nucleobases. Nucleosides, Nucleotides & Nucleic Acids. 24: 1093-5. PMID 16248098 DOI: 10.1081/Ncn-200059179  1
2005 Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Research. 65: 9525-35. PMID 16230418 DOI: 10.1158/0008-5472.Can-05-0529  1
2005 Takahashi Y, Karbowski M, Yamaguchi H, Kazi A, Wu J, Sebti SM, Youle RJ, Wang HG. Loss of Bif-1 suppresses Bax/Bak conformational change and mitochondrial apoptosis. Molecular and Cellular Biology. 25: 9369-82. PMID 16227588 DOI: 10.1128/Mcb.25.21.9369-9382.2005  1
2005 Nefedova Y, Cheng P, Gilkes D, Blaskovich M, Beg AA, Sebti SM, Gabrilovich DI. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. Journal of Immunology (Baltimore, Md. : 1950). 175: 4338-46. PMID 16177074 DOI: 10.4049/Jimmunol.175.7.4338  1
2005 Cloughesy TF, Kuhn J, Robins HI, Abrey L, Wen P, Fink K, Lieberman FS, Mehta M, Chang S, Yung A, DeAngelis L, Schiff D, Junck L, Groves M, Paquette S, ... ... Sebti SM, et al. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6647-56. PMID 16170172 DOI: 10.1200/Jco.2005.10.068  0.01
2005 Turkson J, Zhang S, Mora LB, Burns A, Sebti S, Jove R. Platinum compounds that inhibit constitutive stat3 signaling and induce cell cycle arrest and apoptosis of malignant cells Journal of Biological Chemistry. 280: 32979-32988. PMID 16046414 DOI: 10.1074/Jbc.M502694200  1
2005 Yin H, Lee GI, Sedey KA, Kutzki O, Park HS, Orner BP, Ernst JT, Wang HG, Sebti SM, Hamilton AD. Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL. Journal of the American Chemical Society. 127: 10191-6. PMID 16028929 DOI: 10.1021/Ja050122X  1
2005 Glenn MP, Chang SY, Hucke O, Verlinde CL, Rivas K, Hornéy C, Yokoyama K, Buckner FS, Pendyala PR, Chakrabarti D, Gelb M, Van Voorhis WC, Sebti SM, Hamilton AD. Structurally simple farnesyltransferase inhibitors arrest the growth of malaria parasites. Angewandte Chemie (International Ed. in English). 44: 4903-6. PMID 16007716 DOI: 10.1002/Anie.200500674  1
2005 Chen L, Yin H, Farooqi B, Sebti S, Hamilton AD, Chen J. p53 alpha-Helix mimetics antagonize p53/MDM2 interaction and activate p53. Molecular Cancer Therapeutics. 4: 1019-25. PMID 15956260 DOI: 10.1158/1535-7163.Mct-04-0342  1
2005 Nallan L, Bauer KD, Bendale P, Rivas K, Yokoyama K, Hornéy CP, Pendyala PR, Floyd D, Lombardo LJ, Williams DK, Hamilton A, Sebti S, Windsor WT, Weber PC, Buckner FS, et al. Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. Journal of Medicinal Chemistry. 48: 3704-13. PMID 15916422 DOI: 10.1021/Jm0491039  1
2005 Sun J, Wang DA, Jain RK, Carie A, Paquette S, Ennis E, Blaskovich MA, Baldini L, Coppola D, Hamilton AD, Sebti SM. Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. Oncogene. 24: 4701-9. PMID 15897913 DOI: 10.1038/Sj.Onc.1208391  1
2005 Sebti SM. Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell. 7: 297-300. PMID 15837619 DOI: 10.1016/j.ccr.2005.04.005  1
2005 Yin H, Lee GI, Sedey KA, Rodriguez JM, Wang HG, Sebti SM, Hamilton AD. Terephthalamide derivatives as mimetics of helical peptides: disruption of the Bcl-x(L)/Bak interaction. Journal of the American Chemical Society. 127: 5463-8. PMID 15826183 DOI: 10.1021/Ja0446404  1
2005 Zuckerbraun BS, Barbato JE, Hamilton A, Sebti S, Tzeng E. Inhibition of geranylgeranyltransferase I decreases generation of vascular reactive oxygen species and increases vascular nitric oxide production1 Journal of Surgical Research. 124: 256-263. PMID 15820256 DOI: 10.1016/J.Jss.2004.10.022  1
2005 Yin H, Lee GI, Park HS, Payne GA, Rodriguez JM, Sebti SM, Hamilton AD. Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction. Angewandte Chemie (International Ed. in English). 44: 2704-7. PMID 15765497 DOI: 10.1002/Anie.200462316  1
2005 Mazières J, Tillement V, Allal C, Clanet C, Bobin L, Chen Z, Sebti SM, Favre G, Pradines A. Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells. Experimental Cell Research. 304: 354-64. PMID 15748883 DOI: 10.1016/J.Yexcr.2004.10.019  1
2005 Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, Sebti SM. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene. 24: 3236-45. PMID 15735720 DOI: 10.1038/sj.onc.1208470  1
2005 Zhu K, Gerbino E, Beaupre DM, Mackley PA, Muro-Cacho C, Beam C, Hamilton AD, Lichtenheld MG, Kerr WG, Dalton W, Alsina M, Sebti SM. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood. 105: 4759-66. PMID 15728126 DOI: 10.1182/Blood-2004-11-4307  1
2005 Wang DA, Sebti SM. Palmitoylated cysteine 192 is required for RhoB tumor-suppressive and apoptotic activities. The Journal of Biological Chemistry. 280: 19243-9. PMID 15713677 DOI: 10.1074/Jbc.M411472200  1
2005 Carrico D, Blaskovich MA, Bucher CJ, Sebti SM, Hamilton AD. Design, synthesis, and evaluation of potent and selective benzoyleneurea-based inhibitors of protein geranylgeranyltransferase-I. Bioorganic & Medicinal Chemistry. 13: 677-88. PMID 15653335 DOI: 10.1016/J.Bmc.2004.10.053  1
2005 Woo JT, Nakagawa H, Krecic AM, Nagai K, Hamilton AD, Sebti SM, Stern PH. Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NF kappa B ligand (RANKL) or tumor necrosis factor-alpha (TNF-alpha). Biochemical Pharmacology. 69: 87-95. PMID 15588717 DOI: 10.1016/J.Bcp.2004.08.036  1
2005 Zahouily M, Mezdar A, Elmakssoudi A, Rayadh A, Sebti S, Lazrek HB. Comparison of different Lewis acids supported on natural phosphate as new catalysts for chemoselective dithioacetalization of carbonyl compounds under solvent-free conditions Arkivoc. 2006. DOI: 10.3998/Ark.5550190.0007.203  0.01
2005 Zahouily M, Bahlaouan W, Bahlaouan B, Rayadh A, Sebti S. Catalysis by hydroxyapatite alone and modified by sodium nitrate: a simple and efficient procedure for the construction of carbon-nitrogen bonds in heterogeneous catalysis Arkivoc. 2005. DOI: 10.3998/Ark.5550190.0006.D13  0.01
2005 Zahouily M, Elmakssoudi A, Mezdar A, Rayadh A, Sebti S. Uncatalysed preparation of α-amino phosphonates under solvent free conditions Journal of Chemical Research-S. 2005: 324-327. DOI: 10.3184/0308234054323887  0.01
2005 Badaoui HE, Bazi F, Sokori S, Boulaajaj S, Lazrek HB, Sebti S. One-Pot Synthesis of 3,4-Dihydropyrimidin-2(1H)-ones Using ZnCl2, CuCl2, NiCl2 and CoCl2 Doped Hydroxyapatite Letters in Organic Chemistry. 2: 561-565. DOI: 10.2174/1570178054640750  0.01
2005 Zahouily M, Elmakssoudi A, Mezdar A, Rayadh A, Sebti S, Lazrek HB. Three Components Coupling Catalysed by Na2CaP2O7: Synthesis of α-Amino Phosphonates Under Solvent-Free Conditions at Room Temperature Letters in Organic Chemistry. 2: 428-432. DOI: 10.2174/1570178054405887  0.01
2005 Zahouily M, Charki H, Abrouki Y, Mounir B, Bahlaouan B, Rayadh A, Sebti S. Natural Phosphate Modified with Sodium Nitrate: New Efficient Catalyst for the Construction of a Carbon-Sulfur and Carbon-Nitrogen Bonds Letters in Organic Chemistry. 2: 354-359. DOI: 10.2174/1570178054038830  0.01
2005 Badaoui HE, Bazi F, Tamani S, Boulaajaj S, Zahouily M, Lazrek HB, Sebti S. Lewis Acid–Doped Natural Phosphate: New Catalysts for the One‐Pot Synthesis of 3,4‐Dihydropyrimdin‐2(1H)‐one Synthetic Communications. 35: 2561-2568. DOI: 10.1080/00397910500213963  0.01
2005 Zahouily M, Mezdar A, Rakik J, Elmakssoudi A, Rayadh A, Sebti S. A mild and efficient method for the protection of carbonyl compounds as dithioacetals, dithiolanes and dithianes catalysed by iodine supported on natural phosphate Journal of Molecular Catalysis a-Chemical. 233: 43-47. DOI: 10.1016/J.Molcata.2005.01.043  0.01
2005 Elmakssoudi A, Zahouily M, Mezdar A, Rayadh A, Sebti S. Na2CaP2O7 a new catalyst for the synthesis of α-amino phosphonates under solvent-free conditions at room temperature Comptes Rendus Chimie. 8: 1954-1959. DOI: 10.1016/J.Crci.2005.05.006  0.01
2005 Badaoui HE, Bazi F, Tahir R, Lazrek HB, Sebti S. Synthesis of 3,4-dihydropyrimidin-2-ones catalysed by fluorapatite doped with metal halides Catalysis Communications. 6: 455-458. DOI: 10.1016/J.Catcom.2005.04.003  0.01
2004 Carrico D, Ohkanda J, Kendrick H, Yokoyama K, Blaskovich MA, Bucher CJ, Buckner FS, Van Voorhis WC, Chakrabarti D, Croft SL, Gelb MH, Sebti SM, Hamilton AD. In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. Bioorganic & Medicinal Chemistry. 12: 6517-26. PMID 15556768 DOI: 10.1016/J.Bmc.2004.09.020  1
2004 Epling-Burnette PK, Bai F, Wei S, Chaurasia P, Painter JS, Olashaw N, Hamilton A, Sebti S, Djeu JY, Loughran TP. ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). Oncogene. 23: 9220-9. PMID 15516985 DOI: 10.1038/Sj.Onc.1208122  1
2004 Dasgupta P, Sun J, Wang S, Fusaro G, Betts V, Padmanabhan J, Sebti SM, Chellappan SP. Disruption of the Rb--Raf-1 interaction inhibits tumor growth and angiogenesis. Molecular and Cellular Biology. 24: 9527-41. PMID 15485920 DOI: 10.1128/Mcb.24.21.9527-9541.2004  1
2004 Gasparetto M, Gentry T, Sebti S, O'Bryan E, Nimmanapalli R, Blaskovich MA, Bhalla K, Rizzieri D, Haaland P, Dunne J, Smith C. Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening. Journal of Immunological Methods. 292: 59-71. PMID 15350512 DOI: 10.1016/J.Jim.2004.06.003  1
2004 Paris D, Townsend K, Quadros A, Humphrey J, Sun J, Brem S, Wotoczek-Obadia M, DelleDonne A, Patel N, Obregon DF, Crescentini R, Abdullah L, Coppola D, Rojiani AM, Crawford F, ... Sebti SM, et al. Inhibition of angiogenesis by Abeta peptides. Angiogenesis. 7: 75-85. PMID 15302999 DOI: 10.1023/B:Agen.0000037335.17717.Bf  1
2004 Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, Hamilton AD, Polokoff M, Nicosia SV, Herlyn M, Sebti SM, Cheng JQ. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Research. 64: 4394-9. PMID 15231645 DOI: 10.1158/0008-5472.Can-04-0343  1
2004 Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Cancer Research. 64: 3586-92. PMID 15150116 DOI: 10.1158/0008-5472.Can-03-2673  1
2004 Mazieres J, Antonia T, Daste G, Muro-Cacho C, Berchery D, Tillement V, Pradines A, Sebti S, Favre G. Loss of RhoB expression in human lung cancer progression. Clinical Cancer Research. 10: 2742-2750. PMID 15102679 DOI: 10.1158/1078-0432.Ccr-03-0149  1
2004 Sebti SM, Adjei AA. Farnesyltransferase inhibitors. Seminars in Oncology. 31: 28-39. PMID 14981578  1
2004 Dan HC, Jiang K, Coppola D, Hamilton A, Nicosia SV, Sebti SM, Cheng JQ. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene. 23: 706-15. PMID 14737105 DOI: 10.1038/Sj.Onc.1207171  1
2004 Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, ... ... Sebti SM, et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 103: 3271-7. PMID 14726402 DOI: 10.1182/Blood-2003-08-2764  1
2004 Ohkanda J, Buckner FS, Lockman JW, Yokoyama K, Carrico D, Eastman R, de Luca-Fradley K, Davies W, Croft SL, Van Voorhis WC, Gelb MH, Sebti SM, Hamilton AD. Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents. Journal of Medicinal Chemistry. 47: 432-45. PMID 14711313 DOI: 10.1021/Jm030236O  1
2004 Jiang K, Delarue FL, Sebti SM. EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation Oncogene. 23: 1136-1145. PMID 14647415 DOI: 10.1038/Sj.Onc.1207236  1
2004 Zahouily M, Salah M, Bahlaouan B, Mounir B, Rayadh A, Sebti S. Sodium/fluorapatite as a new solid support for the synthesis of α, β-unsaturated arylsulfones Catalysis Letters. 96: 57-61. DOI: 10.1023/B:Catl.0000029529.98306.5F  0.01
2003 Zhu K, Hamilton AD, Sebti SM. Farnesyltransferase inhibitors as anticancer agents: current status. Current Opinion in Investigational Drugs (London, England : 2000). 4: 1428-35. PMID 14763128  1
2003 Sebti SM, Der CJ. Opinion: Searching for the elusive targets of farnesyltransferase inhibitors. Nature Reviews. Cancer. 3: 945-51. PMID 14737124 DOI: 10.1038/Nrc1234  1
2003 Sun J, Ohkanda J, Coppola D, Yin H, Kothare M, Busciglio B, Hamilton AD, Sebti SM. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice. Cancer Research. 63: 8922-9. PMID 14695209  1
2003 Sebti SM. Blocked Pathways: FTIs Shut Down Oncogene Signals Oncologist. 8: 30-38. PMID 14671226 DOI: 10.1634/Theoncologist.8-Suppl_3-30  1
2003 Buckner F, Yokoyama K, Lockman J, Aikenhead K, Ohkanda J, Sadilek M, Sebti S, Van Voorhis W, Hamilton A, Gelb MH. A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proceedings of the National Academy of Sciences of the United States of America. 100: 15149-53. PMID 14657358 DOI: 10.1073/Pnas.2535442100  1
2003 Ohkanda J, Blaskovich MA, Sebti SM, Hamilton AD. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents. Progress in Cell Cycle Research. 5: 211-7. PMID 14593715  1
2003 Santucci R, Mackley PA, Sebti S, Alsina M. Farnesyltransferase Inhibitors and Their Role in the Treatment of Multiple Myeloma Cancer Control. 10: 384-387. PMID 14581893 DOI: 10.1177/107327480301000505  1
2003 Rochdi A, Taourirte M, Redwane N, Sebti S, Engels JW, Lazrek HB. Doped natural phosphate: a new and environmentally friendly catalyst in nucleoside synthesis. Nucleosides, Nucleotides & Nucleic Acids. 22: 679-81. PMID 14565252 DOI: 10.1081/Ncn-120022699  1
2003 Zhang Z, Wang Y, Lantry LE, Kastens E, Liu G, Hamilton AD, Sebti SM, Lubet RA, You M. Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf. Oncogene. 22: 6257-65. PMID 13679864 DOI: 10.1038/Sj.Onc.1206630  1
2003 Forsberg M, Blomgran R, Lerm M, Särndahl E, Sebti SM, Hamilton A, Stendahl O, Zheng L. Differential effects of invasion by and phagocytosis of Salmonella typhimurium on apoptosis in human macrophages: Potential role of Rho-GTPases and Akt Journal of Leukocyte Biology. 74: 620-629. PMID 12960245 DOI: 10.1189/Jlb.1202586  1
2003 Kurzrock R, Kantarjian HM, Cortes JE, Singhania N, Thomas DA, Wilson EF, Wright JJ, Freireich EJ, Talpaz M, Sebti SM. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood. 102: 4527-34. PMID 12947010 DOI: 10.1182/Blood-2002-11-3359  1
2003 Bordier BB, Ohkanda J, Liu P, Lee SY, Salazar FH, Marion PL, Ohashi K, Meuse L, Kay MA, Casey JL, Sebti SM, Hamilton AD, Glenn JS. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. The Journal of Clinical Investigation. 112: 407-14. PMID 12897208 DOI: 10.1172/Jci17704  1
2003 Peng Y, Li C, Chen L, Sebti S, Chen J. Rescue of mutant p53 transcription function by ellipticine. Oncogene. 22: 4478-87. PMID 12881704 DOI: 10.1038/Sj.Onc.1206777  1
2003 Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Research. 63: 1270-9. PMID 12649187  1
2003 Bolick SC, Landowski TH, Boulware D, Oshiro MM, Ohkanda J, Hamilton AD, Sebti SM, Dalton WS. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia. 17: 451-7. PMID 12592346 DOI: 10.1038/Sj.Leu.2402832  1
2003 Doisneau-Sixou SF, Cestac P, Chouini S, Carroll JS, Hamilton AD, Sebti SM, Poirot M, Balaguer P, Faye JC, Sutherland RL, Favre G. Contrasting effects of prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen receptor-mediated transcriptional activity in MCF-7 cells. Endocrinology. 144: 989-98. PMID 12586776 DOI: 10.1210/En.2002-220726  1
2003 Mazzocca A, Giusti S, Hamilton AD, Sebti SM, Pantaleo P, Carloni V. Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines. Molecular Pharmacology. 63: 159-66. PMID 12488548 DOI: 10.1124/Mol.63.1.159  1
2003 Saber A, Smahi A, Solhy A, Nazih R, Elaabar B, Maizi M, Sebti S. Heterogeneous catalysis of Friedel-Crafts alkylation by the fluorapatite alone and doped with metal halides Journal of Molecular Catalysis a-Chemical. 202: 229-237. DOI: 10.1016/S1381-1169(03)00186-9  0.01
2003 Zahouily M, Abrouki Y, Rayadh A, Sebti S, Dhimane H, David M. Fluorapatite: efficient catalyst for the Michael addition Tetrahedron Letters. 44: 2463-2465. DOI: 10.1016/S0040-4039(03)00323-X  0.01
2003 Zahouily M, Abrouki Y, Bahlaouan B, Rayadh A, Sebti S. Hydroxyapatite: new efficient catalyst for the Michael addition Catalysis Communications. 4: 521-524. DOI: 10.1016/J.Catcom.2003.08.001  0.01
2002 Allal C, Pradines A, Hamilton AD, Sebti SM, Favre G. Farnesylated RhoB prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase I inhibitor GGTI-298. Cell Cycle (Georgetown, Tex.). 1: 430-7. PMID 12548020 DOI: 10.4161/Cc.1.6.272  1
2002 Jackson RJ, Adnane J, Coppola D, Cantor A, Sebti SM, Pledger WJ. Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models. Oncogene. 21: 8486-97. PMID 12466968 DOI: 10.1038/Sj.Onc.1205946  1
2002 Adnane J, Muro-Cacho C, Mathews L, Sebti SM, Muñoz-Antonia T. Suppression of rho B expression in invasive carcinoma from head and neck cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 2225-32. PMID 12114424  1
2002 Crespo NC, Delarue F, Ohkanda J, Carrico D, Hamilton AD, Sebti SM. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status. Cell Death and Differentiation. 9: 702-9. PMID 12058275 DOI: 10.1038/Sj.Cdd.4401023  1
2002 Ohkanda J, Knowles DB, Blaskovich MA, Sebti SM, Hamilton AD. Inhibitors of protein farnesyltransferase as novel anticancer agents. Current Topics in Medicinal Chemistry. 2: 303-23. PMID 11944822 DOI: 10.2174/1568026023394281  1
2002 Walters CE, Pryce G, Hankey DJ, Sebti SM, Hamilton AD, Baker D, Greenwood J, Adamson P. Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis. Journal of Immunology (Baltimore, Md. : 1950). 168: 4087-94. PMID 11937568 DOI: 10.4049/Jimmunol.168.8.4087  1
2002 Li X, Liu L, Tupper JC, Bannerman DD, Winn RK, Sebti SM, Hamilton AD, Harlan JM. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. The Journal of Biological Chemistry. 277: 15309-16. PMID 11839765 DOI: 10.1074/Jbc.M201253200  1
2002 Ohkanda J, Lockman JW, Kothare MA, Qian Y, Blaskovich MA, Sebti SM, Hamilton AD. Design and synthesis of potent nonpeptidic farnesyltransferase inhibitors based on a terphenyl scaffold. Journal of Medicinal Chemistry. 45: 177-88. PMID 11754590 DOI: 10.1021/Jm0103099  1
2002 Adnane J, Seijo E, Chen Z, Bizouarn F, Leal M, Sebti SM, Muñoz-Antonia T. Rhob, not RhoA, represses the transcription of the transforming growth factor β type II receptor by a mechanism involving activator protein 1 Journal of Biological Chemistry. 277: 8500-8507. PMID 11741970 DOI: 10.1074/Jbc.M104367200  1
2001 Kucich U, Rosenbloom JC, Herrick DJ, Abrams WR, Hamilton AD, Sebti SM, Rosenbloom J. Signaling events required for transforming growth factor-beta stimulation of connective tissue growth factor expression by cultured human lung fibroblasts. Archives of Biochemistry and Biophysics. 395: 103-12. PMID 11673871 DOI: 10.1006/Abbi.2001.2571  1
2001 Delarue FL, Taylor BS, Sebti SM. Ras and RhoA suppress whereas RhoB enhances cytokine-induced transcription of nitric oxide synthase-2 in human normal liver AKN-1 cells and lung cancer A-549 cells Oncogene. 20: 6531-6537. PMID 11641777 DOI: 10.1038/Sj.Onc.1204801  1
2001 Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Haura E, Laudano A, Sebti S, Hamilton AD, Jove R. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. The Journal of Biological Chemistry. 276: 45443-55. PMID 11579100 DOI: 10.1074/Jbc.M107527200  1
2001 Finder JD, Petrus JL, Hamilton A, Villavicencio RT, Pitt BR, Sebti SM. Signal transduction pathways of IL-1beta-mediated iNOS in pulmonary vascular smooth muscle cells. American Journal of Physiology. Lung Cellular and Molecular Physiology. 281: L816-23. PMID 11557585 DOI: 10.1152/Ajplung.2001.281.4.L816  1
2001 Teng S, Sun J, Irby R, Hamilton AD, Sebti S, Yeatman TJ. v-Src transformation is mediated through farnesylated proteins. The Journal of Surgical Research. 99: 343-6. PMID 11469908 DOI: 10.1006/Jsre.2001.6184  1
2001 Ohkanda J, Lockman JW, Yokoyama K, Gelb MH, Croft SL, Kendrick H, Harrell MI, Feagin JE, Blaskovich MA, Sebti SM, Hamilton AD. Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity. Bioorganic & Medicinal Chemistry Letters. 11: 761-4. PMID 11277514 DOI: 10.1016/S0960-894X(01)00055-5  1
2001 Sun J, Nam S, Lee CS, Li B, Coppola D, Hamilton AD, Dou QP, Sebti SM. CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. Cancer Research. 61: 1280-4. PMID 11245420  1
2001 Crespo NC, Ohkanda J, Yen TJ, Hamilton AD, Sebti SM. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. The Journal of Biological Chemistry. 276: 16161-7. PMID 11154688 DOI: 10.1074/jbc.M006213200  1
2001 Bennazha J, Zahouily M, Sebti S, Boukhari A, Holt EM. Na2CaP2O7, a new catalyst for Knoevenagel reaction Catalysis Communications. 2: 101-104. DOI: 10.1016/S1566-7367(01)00015-2  0.01
2000 Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene. 19: 6584-93. PMID 11426643 DOI: 10.1038/Sj.Onc.1204146  1
2000 Sebti SM, Hamilton AD. Design of growth factor antagonists with antiangiogenic and antitumor properties. Oncogene. 19: 6566-73. PMID 11426641 DOI: 10.1038/Sj.Onc.1204121  1
2000 Adnane J, Bizouarn FA, Chen Z, Ohkanda J, Hamilton AD, Munoz-Antonia T, Sebti SM. Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta. Oncogene. 19: 5525-33. PMID 11114730 DOI: 10.1038/Sj.Onc.1203920  1
2000 Adnane J, Jackson RJ, Nicosia SV, Cantor AB, Pledger WJ, Sebti SM. Loss of p21WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model. Oncogene. 19: 5338-47. PMID 11103935 DOI: 10.1038/Sj.Onc.1203956  1
2000 Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Expert Opinion On Investigational Drugs. 9: 2767-82. PMID 11093352 DOI: 10.1517/13543784.9.12.2767  1
2000 Dey A, She H, Kim L, Boruch A, Guris DL, Carlberg K, Sebti SM, Woodley DT, Imamoto A, Li W. Colony-stimulating factor-1 receptor utilizes multiple signaling pathways to induce cyclin D2 expression Molecular Biology of the Cell. 11: 3835-3848. PMID 11071910 DOI: 10.1091/Mbc.11.11.3835  1
2000 Sebti SM, Hamilton AD. Inhibition of Rho GTPases using protein geranylgeranyltransferase I inhibitors. Methods in Enzymology. 325: 381-8. PMID 11036620 DOI: 10.1016/S0076-6879(00)25459-1  1
2000 Wei S, Gilvary DL, Corliss BC, Sebti S, Sun J, Straus DB, Leibson PJ, Trapani JA, Hamilton AD, Weber MJ, Djeu JY. Direct tumor lysis by NK cells uses a Ras-independent mitogen-activated protein kinase signal pathway. Journal of Immunology (Baltimore, Md. : 1950). 165: 3811-9. PMID 11034387 DOI: 10.4049/Jimmunol.165.7.3811  1
2000 Blaskovich MA, Lin Q, Delarue FL, Sun J, Park HS, Coppola D, Hamilton AD, Sebti SM. Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice. Nature Biotechnology. 18: 1065-70. PMID 11017044 DOI: 10.1038/80257  1
2000 Coxon FP, Helfrich MH, Hof RV, Sebti S, Ralston SH, Hamilton A, Rogers MJ. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. Journal of Bone and Mineral Research. 15: 1467-1476. PMID 10934645 DOI: 10.1359/Jbmr.2000.15.8.1467  1
2000 Cohen-Jonathan E, Muschel RJ, Gillies McKenna W, Evans SM, Cerniglia G, Mick R, Kusewitt D, Sebti SM, Hamilton AD, Oliff A, Kohl N, Gibbs JB, Bernhard EJ. Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiation Research. 154: 125-32. PMID 10931682 DOI: 10.1667/0033-7587(2000)154[0125:Fiptae]2.0.Co;2  1
2000 Rosenbloom J, Saitta B, Gaidarova S, Sandorfi N, Rosenbloom JC, Abrams WR, Hamilton AD, Sebti SM, Kucich U, Jimenez SA. Inhibition of type I collagen gene expression in normal and systemic sclerosis fibroblasts by a specific inhibitor of geranylgeranyl transferase I. Arthritis and Rheumatism. 43: 1624-32. PMID 10902768 DOI: 10.1002/1529-0131(200007)43:7<1624::Aid-Anr28>3.0.Co;2-E  1
2000 Allal C, Favre G, Couderc B, Salicio S, Sixou S, Hamilton AD, Sebti SM, Lajoie-Mazenc I, Pradines A. RhoA prenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription. The Journal of Biological Chemistry. 275: 31001-8. PMID 10896672 DOI: 10.1074/Jbc.M005264200  1
2000 Chen Z, Sun J, Pradines A, Favre G, Adnane J, Sebti SM. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice Journal of Biological Chemistry. 275: 17974-17978. PMID 10770919 DOI: 10.1074/jbc.C000145200  1
2000 Kucich U, Rosenbloom JC, Shen G, Abrams WR, Hamilton AD, Sebti SM, Rosenbloom J. TGF-beta1 stimulation of fibronectin transcription in cultured human lung fibroblasts requires active geranylgeranyl transferase I, phosphatidylcholine-specific phospholipase C, protein kinase C-delta, and p38, but not erk1/erk2. Archives of Biochemistry and Biophysics. 374: 313-24. PMID 10666313 DOI: 10.1006/Abbi.1999.1625  1
2000 Boota A, Johnson B, Lee KL, Blaskovich MA, Liu SX, Kagan VE, Hamilton A, Pitt B, Sebti SM, Davies P. Prenyltransferase inhibitors block superoxide production by pulmonary vascular smooth muscle American Journal of Physiology - Lung Cellular and Molecular Physiology. 278. PMID 10666117 DOI: 10.1152/Ajplung.2000.278.2.L329  1
2000 Carloni V, Pinzani M, Giusti S, Romanelli RG, Parola M, Bellomo G, Failli P, Hamilton AD, Sebti SM, Laffi G, Gentilini P. Tyrosine phosphorylation of focal adhesion kinase by PDGF is dependent on ras in human hepatic stellate cells. Hepatology (Baltimore, Md.). 31: 131-40. PMID 10613738 DOI: 10.1002/Hep.510310121  1
2000 Lantry LE, Zhang Z, Yao R, Crist KA, Wang Y, Ohkanda J, Hamilton AD, Sebti SM, Lubet RA, You M. Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis. 21: 113-6. PMID 10607742 DOI: 10.1093/Carcin/21.1.113  1
2000 Jiang K, Coppola D, Crespo NC, Nicosia SV, Hamilton AD, Sebti SM, Cheng JQ. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Molecular and Cellular Biology. 20: 139-48. PMID 10594016 DOI: 10.1128/Mcb.20.1.139-148.2000  1
2000 Sebti SM. Guest editor Oncogene. 19: 6549. DOI: 10.1038/Sj.Onc.1204089  1
2000 Sebti S, Nazih R, Tahir R, Salhi L, Saber A. Fluorapatite: new solid catalyst of the Knoevenagel reaction in heterogeneous media without solvent Applied Catalysis a-General. 197. DOI: 10.1016/S0926-860X(99)00492-5  0.01
2000 Kotharé MA, Ohkanda J, Lockman JW, Qian Y, Blaskovich MA, Sebti SM, Hamilton AD. Development of a tripeptide mimetic strategy for the inhibition of protein farnesyltransferase Tetrahedron. 56: 9833-9841.  1
1999 Bowman T, Yu H, Sebti S, Dalton W, Jove R. Signal Transducers and Activators of Transcription: Novel Targets for Anticancer Therapeutics. Cancer Control : Journal of the Moffitt Cancer Center. 6: 427-435. PMID 10758575 DOI: 10.1177/107327489900600501  1
1999 Qian Y, Marugan JJ, Fossum RD, Vogt A, Sebti SM, Hamilton AD. Probing the hydrophobic pocket of farnesyltransferase: aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors. Bioorganic & Medicinal Chemistry. 7: 3011-24. PMID 10658608 DOI: 10.1016/S0968-0896(99)00252-7  1
1999 Liu L, Moesner P, Kovach NL, Bailey R, Hamilton AD, Sebti SM, Harlan JM. Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s). The Journal of Biological Chemistry. 274: 33334-40. PMID 10559211 DOI: 10.1074/Jbc.274.47.33334  1
1999 Pollack IF, Bredel M, Erff M, Hamilton AD, Sebti SM. Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II--preclinical studies in a nude mouse model. Neurosurgery. 45: 1208-14; discussion . PMID 10549939 DOI: 10.1097/00006123-199911000-00039  1
1999 Mazet JL, Padieu M, Osman H, Maume G, Mailliet P, Dereu N, Hamilton AD, Lavelle F, Sebti SM, Maume BF. Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells. Febs Letters. 460: 235-40. PMID 10544242 DOI: 10.1016/S0014-5793(99)01355-1  1
1999 Turkson J, Bowman T, Adnane J, Zhang Y, Djeu JY, Sekharam M, Frank DA, Holzman LB, Wu J, Sebti S, Jove R. Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Molecular and Cellular Biology. 19: 7519-7528. PMID 10523640 DOI: 10.1128/Mcb.19.11.7519  1
1999 Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RD, Hamilton AD, Sebti SM. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, taxol, and gemcitabine Cancer Research. 59: 4919-4926. PMID 10519405  1
1999 O'Connor SJ, Barr KJ, Wang L, Sorensen BK, Tasker AS, Sham H, Ng SC, Cohen J, Devine E, Cherian S, Saeed B, Zhang H, Lee JY, Warner R, Tahir S, ... ... Sebti SM, et al. Second-generation peptidomimetic inhibitors of protein farnesyltransferase demonstrating improved cellular potency and significant in vivo efficacy. Journal of Medicinal Chemistry. 42: 3701-10. PMID 10479301 DOI: 10.1021/Jm9901935  1
1999 Cohen-Jonathan E, Toulas C, Ader I, Monteil S, Allal C, Bonnet J, Hamilton AD, Sebti SM, Daly-Schveitzer N, Favre G. The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2- induced radioresistance in HeLa cells expressing wild-type RAS Radiation Research. 152: 404-411. PMID 10477917 DOI: 10.2307/3580225  1
1999 Vasudevan A, Qian Y, Vogt A, Blaskovich MA, Ohkanda J, Sebti SM, Hamilton AD. Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I Journal of Medicinal Chemistry. 42: 1333-1340. PMID 10212118 DOI: 10.1021/Jm9900873  1
1999 Sun J, Qian Y, Chen Z, Marfurt J, Hamilton AD, Sebti SM. The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin- dependent kinase inhibitors: A potential mechanism for GGTI-298 antitumor activity Journal of Biological Chemistry. 274: 6930-6934. PMID 10066746 DOI: 10.1074/Jbc.274.11.6930  1
1999 Lazrek HB, Rochdi A, Kabbaj Y, Taourirte M, Sebti S. Zinc Chloride Doped Natural Phosphate as 1,3-Dipolar Cycloaddition Catalyst Synthetic Communications. 29: 1057-1063. DOI: 10.1080/00397919908086072  0.01
1998 Adnane J, Bizouarn FA, Qian Y, Hamilton AD, Sebti SM. p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor β- and Sp1- responsive element: Involvement of the small GTPase RhoA Molecular and Cellular Biology. 18: 6962-6970. PMID 9819384 DOI: 10.1128/Mcb.18.12.6962  1
1998 Kucich U, Rosenbloom JC, Shen G, Abrams WR, Blaskovich MA, Hamilton AD, Ohkanda J, Sebti SM, Rosenbloom J. Requirement for geranylgeranyl transferase I and acyl transferase in the TGF-β-stimulated pathway leading to elastin mRNA stabilization Biochemical and Biophysical Research Communications. 252: 111-116. PMID 9813154 DOI: 10.1006/Bbrc.1998.9544  1
1998 Stark WW, Blaskovich MA, Johnson BA, Qian Y, Vasudevan A, Pitt B, Hamilton AD, Sebti SM, Davies P. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells American Journal of Physiology - Lung Cellular and Molecular Physiology. 275. PMID 9688935 DOI: 10.1152/Ajplung.1998.275.1.L55  1
1998 Bredel M, Pollack IF, Freund JM, Hamilton AD, Sebti SM. Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth Neurosurgery. 43: 124-132. PMID 9657198 DOI: 10.1097/00006123-199807000-00081  1
1998 Qian Y, Vogt A, Vasudevan A, Sebti SM, Hamilton AD. Selective inhibition of type-I geranylgeranyltransferase in vitro and in whole cells by CAAL peptidomimetics Bioorganic and Medicinal Chemistry. 6: 293-299. PMID 9568283 DOI: 10.1016/S0968-0896(97)10040-2  1
1998 Bernhard EJ, McKenna WG, Hamilton AD, Sebti SM, Qian Y, Wu JM, Muschel RJ. Inhibiting ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes Cancer Research. 58: 1754-1761. PMID 9563495  1
1998 Sun J, Qian Y, Hamilton AD, Sebti SM. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in node mouse xenografts Oncogene. 16: 1467-1473. PMID 9525745 DOI: 10.1038/Sj.Onc.1201656  1
1998 Sebti SM, Hamilton AD. New approaches to anticancer drug design based on the inhibition of farnesyltransferase Drug Discovery Today. 3: 26-33. DOI: 10.1016/S1359-6446(97)01122-7  1
1997 Sebti SM, Hamilton AD. Anticancer activity of farnesyltransferase and geranylgeranyltransferase I inhibitors: prospects for drug development. Expert Opinion On Investigational Drugs. 6: 1711-4. PMID 15989575 DOI: 10.1517/13543784.6.11.1711  1
1997 Vogt A, Sun J, Qian Y, Hamilton AD, Sebti SM. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SD11) in a p53-independent manner Journal of Biological Chemistry. 272: 27224-27229. PMID 9341167 DOI: 10.1074/Jbc.272.43.27224  1
1997 Sebti SM, Hamilton AD. Inhibition of Ras prenylation: A novel approach to cancer chemotherapy Pharmacology and Therapeutics. 74: 103-114. PMID 9336018 DOI: 10.1016/S0163-7258(97)00014-4  1
1997 Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines Oncogene. 15: 1283-1288. PMID 9315095 DOI: 10.1038/Sj.Onc.1201296  1
1997 Lerner EC, Hamilton AD, Sebti SM. Inhibition of Ras prenylation: A signaling target for novel anti-cancer drug design Anti-Cancer Drug Design. 12: 229-238. PMID 9199657  1
1997 Qian Y, Sebti SM, Hamilton AD. Farnesyltransferase as a target for anticancer drug design Biopolymers. 43: 25-41. PMID 9174410 DOI: 10.1002/(Sici)1097-0282(1997)43:1<25::Aid-Bip4>3.0.Co;2-2  1
1997 Miquel K, Pradines A, Sun J, Qian Y, Hamilton AD, Sebti SM, Favre G. GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2- M enrichment in A549 cells Cancer Research. 57: 1846-1850. PMID 9157972  1
1997 Finder JD, Litz JL, Blaskovich MA, McGuire TF, Qian Y, Hamilton AD, Davies P, Sebti SM. Inhibition of protein geranylgeranylation causes a superinduction of nitric-oxide synthase-2 by interleukin-1beta in vascular smooth muscle cells. The Journal of Biological Chemistry. 272: 13484-8. PMID 9153192 DOI: 10.1074/Jbc.272.21.13484  1
1997 Clark GJ, Kinch MS, Rogers-Graham K, Sebti SM, Hamilton AD, Der CJ. The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation Journal of Biological Chemistry. 272: 10608-10615. PMID 9099708 DOI: 10.1074/Jbc.272.16.10608  1
1997 McGuire TF, Sebti SM. Geranylgeraniol potentiates lovastatin inhibition of oncogenic H-Ras processing and signaling while preventing cytotoxicity Oncogene. 14: 305-312. PMID 9018116 DOI: 10.1038/Sj.Onc.1200819  1
1997 Pollack IF, Bredel M, Freund JM, Sebti SM. Inhibition of malignant glioma growth by blocking p21RAS processing Clinical Neurology and Neurosurgery. 99. DOI: 10.1016/S0303-8467(97)82340-2  1
1996 Vogt A, Qian Y, McGuire TF, Hamilton AD, Sebti SM. Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts Oncogene. 13: 1991-1999. PMID 8934546  1
1996 McGuire TF, Qian Y, Vogt A, Hamilton AD, Sebti SM. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation Journal of Biological Chemistry. 271: 27402-27407. PMID 8910319 DOI: 10.1074/Jbc.271.44.27402  1
1996 Sebti SM, Hamilton AD. Rational design of Ras prenyltransferase inhibitors as potential anticancer drugs Biochemical Society Transactions. 24: 692-699. PMID 8878828 DOI: 10.1042/Bst0240692  1
1996 Pei Z, Sebti SM. Cys 102 and His 398 are required for bleomycin-inactivating activity but not for hexamer formation of yeast bleomycin hydrolase Biochemistry. 35: 10751-10756. PMID 8718865 DOI: 10.1021/Bi9605447  1
1996 Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton AD, Muschel RJ, McKenna WG. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts Cancer Research. 56: 1727-1730. PMID 8620483  1
1996 Xu XQ, McGuire TF, Blaskovich MA, Sebti SM, Romero G. Lovastatin inhibits the stimulation of mitogen-activated protein kinase by insulin in HIRcB fibroblasts Archives of Biochemistry and Biophysics. 326: 233-237. PMID 8611028 DOI: 10.1006/Abbi.1996.0070  1
1996 Qian Y, Vogt A, Sebti SM, Hamilton AD. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors Journal of Medicinal Chemistry. 39: 217-223. PMID 8568811 DOI: 10.1021/Jm950414G  1
1996 Stark W, Sebti SM, Davies P. Constitutlvely active ras reduces the incidence of apoptosis in nffl 3t3 cells Faseb Journal. 10.  1
1995 Vogt A, Qian Y, Blaskovich MA, Fossum RD, Hamilton AD, Sebti SM. A non-peptide mimetic of Ras-CAAX: Selective inhibition of farnesyltransferase and Ras processing Journal of Biological Chemistry. 270: 660-664. PMID 7822292 DOI: 10.1074/Jbc.270.2.660  1
1995 Sun J, Sebti SM, Qian Y, Hamilton AD. Ras CAAX Peptidomimetic FTI 276 Selectively Blocks Tumor Growth in Nude Mice of a Human Lung Carcinoma with K-Ras Mutation and p53 Deletion Cancer Research. 55: 4243-4247. PMID 7671229  1
1995 McGuire TF, Qian Y, Blaskovich MA, Fossum RD, Sun J, Marlowe T, Corey SJ, Wathen SP, Vogt A, Hamilton AD. CAAX peptidomimetic FTI-244 decreases platelet-derived growth factor receptor tyrosine phosphorylation levels and inhibits stimulation of phosphatidylinositol 3-kinase but not mitogen-activated protein kinase. Biochemical and Biophysical Research Communications. 214: 295-303. PMID 7669049 DOI: 10.1006/Bbrc.1995.2287  1
1995 Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Vogt A, Sun J, Cox AD, Der CJ, Hamilton AD, Sebti SM. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes Journal of Biological Chemistry. 270: 26802-26806. PMID 7592920 DOI: 10.1074/Jbc.270.45.26802  1
1995 Lernert EC, Qian Y, Hamilton AD, Sebti SM. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor Journal of Biological Chemistry. 270: 26770-26773. PMID 7592913 DOI: 10.1074/Jbc.270.45.26770  1
1995 Sebti SM. Burkitt lymphoma daudi cells contain two distinct farnesyltransferases with different divalent cation requirements Biochemistry. 34: 12398-12403. PMID 7547984 DOI: 10.1021/Bi00038A037  1
1995 Kauffmann RC, Qian Y, Vogt A, Sebti SM, Hamilton AD, Carthew RW. Activated Drosophila Ras1 is selectively suppressed by isoprenyl transferase inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 92: 10919-23. PMID 7479910 DOI: 10.1073/Pnas.92.24.10919  1
1995 Pei Z, Calmels TPG, Creutz CE, Sebti SM. Yeast cysteine proteinase gene ycp1 induces resistance to bleomycin in mammalian cells Molecular Pharmacology. 48: 676-681. PMID 7476893  1
1995 Hamilton AD, Sebti SM. Inhibitors of ras farnesyltransferase as novel antitumor agents Drug News and Perspectives. 8: 138-145.  1
1994 Weng W, Reynolds IJ, Jani JP, Blaskovich M, Sebti SM, Davies P, Pitt BR. Desensitization of 5HT2 receptors by protein kinase C activation in distal pulmonary vascular smooth muscle cells in culture. Microcirculation (New York, N.Y. : 1994). 1: 129-35. PMID 8790584 DOI: 10.3109/10739689409148268  1
1994 Qian Y, Blaskovich MA, Saleem M, Seong CM, Wathen SP, Hamilton AD, Sebti SM. Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyltransferase Journal of Biological Chemistry. 269: 12410-12413. PMID 8175645  1
1994 Lazo JS, Sebti SM. Bleomycin Cancer Chemotherapy and Biological Response Modifiers. 15: 44-50. PMID 7540032  1
1994 Mcguire TF, Xu XQ, Corey SJ, Romero GG, Sebti SM. Lovastatin Disrupts Early Events in Insulin Signaling: A Potential Mechanism of Lovastatins Anti-Mitogenic Activity Biochemical and Biophysical Research Communications. 204: 399-406. PMID 7524501 DOI: 10.1006/Bbrc.1994.2472  1
1994 Qian Y, Blaskovich MA, Seong CM, Vogt A, Hamilton AD, Sebti SM. Peptidomimetic inhibitors of p21ras farnesyltransferase: Hydrophobic functionalization leads to disruption of p21ras membrane association in whole cells Bioorganic and Medicinal Chemistry Letters. 4: 2579-2584. DOI: 10.1016/S0960-894X(01)80287-0  1
1993 Nigam M, Seong CM, Qian Y, Hamilton AD, Sebti SM. Potent inhibition of human tumor p21ras farnesyltransferase by A1A2-lacking p21ras CA1A2X peptidomimetics. The Journal of Biological Chemistry. 268: 20695-8. PMID 8407887  1
1993 McGuire TF, Corey SJ, Sebti SM. Lovastatin inhibits platelet-derived growth factor (PDGF) stimulation of phosphatidylinositol 3-kinase activity as well as association of p85 subunit to tyrosine-phosphorylated PDGF receptor Journal of Biological Chemistry. 268: 22227-22230. PMID 7693661  1
1992 Morris G, Mistry JS, Jani JP, Mignano JE, Sebti SM, Lazo JS. Neutralization of bleomycin hydrolase by an epitope-specific antibody. Molecular Pharmacology. 42: 57-62. PMID 1378925  1
1992 Jani JP, Mistry JS, Morris G, Lazo JS, Sebti SM. In vivo sensitization of human lung carcinoma to bleomycin by the cysteine proteinase inhibitor E-64. Oncology Research. 4: 59-63. PMID 1375852  1
1992 Jani JP, Mistry JS, Morris G, Davies P, Lazo JS, Sebti SM. In vivo circumvention of human colon carcinoma resistance to bleomycin. Cancer Research. 52: 2931-7. PMID 1374681  1
1992 Mistry JS, Jani JP, Morris G, Mujumdar RB, Reynolds IJ, Sebti SM, Lazo JS. Synthesis and evaluation of fluoromycin: a novel fluorescence-labeled derivative of talisomycin S10b. Cancer Research. 52: 709-18. PMID 1370650  1
1991 Sebti SM, Tkalcevic GT, Jani JP. Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice Cancer Communications. 3: 141-147. PMID 2043425  1
1991 Lazo JS, Sebti SM. Bleomycins Cancer Chemotherapy and Biological Response Modifiers. 12: 51-58. PMID 1718378  1
1991 Morris G, Mistry JS, Jani JP, Sebti SM, Lazo JS. Cysteine proteinase inhibitors and bleomycin-sensitive and -resistant cells. Biochemical Pharmacology. 41: 1559-66. PMID 1710457 DOI: 10.1016/0006-2952(91)90154-W  1
1991 Sebti SM, Jani JP, Mistry JS, Gorelik E, Lazo JS. Metabolic inactivation: a mechanism of human tumor resistance to bleomycin. Cancer Research. 51: 227-32. PMID 1703034  1
1990 Lazo JS, Hoyt DG, Sebti SM, Pitt BR. Bleomycin: A pharmacologic tool in the study of the pathogenesis of interstitial pulmonary fibrosis Pharmacology and Therapeutics. 47: 347-358. PMID 1705351 DOI: 10.1016/0163-7258(90)90061-6  1
1990 Mistry JS, Sebti SM, Lazo JS. Separation of bleomycins and their deamido metabolites by high-performance cation-exchange chromatography. Journal of Chromatography. 514: 86-90. PMID 1698802 DOI: 10.1016/S0021-9673(01)89380-8  1
1989 Sebti SM, Mignano JE, Jani JP, Srimatkandada S, Lazo JS. Bleomycin hydrolase: Molecular cloning, sequencing, and biochemical studies reveal membership in the cysteine proteinase family Biochemistry. 28: 6544-6548. PMID 2477059  1
1989 Sebti SM, Deleon JC, Ma LT, Hecht SM, Lazo JS. Substrate specificity of bleomycin hydrolase Biochemical Pharmacology. 38: 141-147. PMID 2462878 DOI: 10.1016/0006-2952(89)90160-3  1
1988 Sebti SM, Lazo JS. Metabolic inactivation of bleomycin analogs by bleomycin hydrolase Pharmacology and Therapeutics. 38: 321-329. PMID 2461572 DOI: 10.1016/0163-7258(88)90009-5  1
1987 Sebti SM. Purification, characterization, and amino acid composition of rabbit pulmonary bleomycin hydrolase Biochemistry. 26: 4213-4219. PMID 3117099 DOI: 10.1021/Bi00388A006  1
1987 Sebti SM, Lazo JS. Separation of the protective enzyme bleomycin hydrolase from rabbit pulmonary aminopeptidases Biochemistry. 26: 432-437. PMID 3103681 DOI: 10.1021/Bi00376A014  1
1986 Baird WM, Sebti SM, Reinsvold LA. Metabolic activation of benzo(a)pyrene in SENCAR and BALB/c mouse embryo cell cultures Environmental Health Perspectives. 45-52. PMID 3780631 DOI: 10.1289/Ehp.866845  1
1985 Sebti SM, Moynihan CG, Anderson JN, Baird WM. Benzo[a]pyrene-dna adduct formation in target and activator cells in a wistar rat embryo cell-mediated v79 cell mutation assay Carcinogenesis. 6: 983-988. PMID 4017178 DOI: 10.1093/Carcin/6.7.983  1
1985 Sebti SM, Pruess-Schwartz D, Baird WM. Species- and Length of Exposure-dependent Differences in the Benzo(a)pyrene:DNA Adducts Formed in Embryo Cell Cultures from Mice, Rats, and Hamsters Cancer Research. 45: 1594-1600. PMID 3978626  1
1985 Sebti SM, Smolarek TA, Salmon CP, Baird WM. 7,12-Dimethylbenz[a]anthracene-DNA adduct formation in Wistar rat and Syrian hamster embryo cell cultures Chemico-Biological Interactions. 56: 1-12. PMID 3935336 DOI: 10.1016/0009-2797(85)90035-3  1
1984 Pruess-Schwartz D, Sebti SM, Gilham PT, Baird WM. Analysis of benzo(a)pyrene:DNA adducts formed in cells in culture by immobilized boronate chromatography Cancer Research. 44: 4104-4110. PMID 6331665  1
1984 Sebti SM, Baird WM. Rat liver homogenate (S9)-mediated binding of benzo[a]pyren to DNA in V79 cells, V79 cell nuclei and aqueous solution Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis. 125: 307-314. PMID 6321977 DOI: 10.1016/0027-5107(84)90080-0  1
1982 Sebti SM, Baird WM, Knowles BB, Diamond L. Benzo[a]pyrene-DNA adduct formation in target cells in a cell-mediated mutation assay Carcinogenesis. 3: 1317-1320. PMID 6817937 DOI: 10.1093/Carcin/3.11.1317  1
Show low-probability matches.